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Abstract 
Fetal growth restriction (FGR) is a common and potentially life-threatening complication 
that affects 5-10% of human pregnancies. Maternal genetic predisposition and fetal male 
sex are known risk factors, but the underlying mechanisms are unknown. To study a 
known maternal genetic risk factor and the impact of fetal sex, we employed a published 
transgenic (TG) mouse model, which was designed to mimic a common human 
angiotensinogen (AGT) promoter variant associated with a 20% increase in circulating 
AGT levels. We hypothesized that TG dams would deliver growth restricted pups and 
that the underlying mechanism would be related to differences in maternal uterine 
pregnancy-induced vascular remodeling, abnormal blood flow to the placenta, and 
placental damage. In addition, since growth restricted human males are at an increased 
risk of developing adult onset hypertension, which has been associated with reduced 
nephron development, we tested for developmental programming in our mouse model 
and the impact of fetal sex. Our results show that TG dams have reduced uterine and 
placental angiogenesis when their pups were males, but relatively normal angiogenesis in 
the female siblings compared with wild-type controls. The uterine placental bed in TG 
dams had abnormal pro-angiogenic/anti-angiogenic expression ratios that were related to 
differences in uterine natural killer cell activation and fetal sex. The abnormal phenotype 
could be rescued by delivering vascular endothelial growth factor (VEGF) to uterine 
endothelial cells. Male progeny from TG dams had abnormal kidney epigenetic changes, 
fewer nephrons as adults, and they developed stress-induced hypertension. We conclude 
that the combination of maternal genetic risk and fetal male sex affect uteroplacental 
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Dissertation Introduction:  
New Insights into the Roles of Maternal Genotype and Fetal Sex in the 
Pathophysiology of Placental Insufficiency 
 
 
 Fetal growth restriction (FGR) is a common and potentially life-threatening 
complication of pregnancy (1). It is defined as birthweight below the 10th percentile for 
gestational age (2). Not only does FGR increase perinatal morbidity and mortality, but 
accumulating evidence suggests the relative lack of appropriate nutrition in utero leads to 
profound epigenetic affects and abnormal fetal organ development culminating in a 
significantly increased risk of adult onset diseases like hypertension, diabetes, and 
cardiovascular disease (3, 4). FGR is a multifactorial disease, but the most common 
association is relative “placental insufficiency,” which may be defined as reduced 
maternal nutrient supply (e.g. low protein diet, relative hypoxia [altitude]), or increased 
fetoplacental demand (exceptionally large placenta and/or baby, which is observed in 
maternal obesity and gestational diabetes; or multiple gestations [twins; triplets]) (1). 
 The underlying cause of placental insufficiency is not well understood, but the 
clinical syndrome includes more than just FGR: gestational hypertension (preeclampsia), 
preterm labor not caused by intra-amniotic infection, and developmental programming of 
many adult onset diseases are often comorbid (5–10). Abnormal blood flow to the 
placenta is thought to be the most common cause of placental insufficiency in these 
multifactorial syndromes (6), but the mechanisms affecting blood flow to the placenta are 
not well understood. The overarching hypothesis tested in this dissertation is that 
2 
differences in uteroplacental arterial growth and architecture may explain differences in 
uteroplacental blood flow and pregnancy outcomes, including developmental 
programming of adult onset disease.  
Developmental Origins of Health and Disease (DOHAD)  
 Developmental Origins of Health and Disease (DOHAD) explores how early life 
events, from effects on the oocyte to gestational conditions to childhood illness, have 
impact on later adult onset disease (11). These events are often referred to as the “Barker 
Hypothesis” for David Barker, who described “programming” events, where early 
changes in structure or function resulted in increased risk of adult disease (12, 13). Some 
of the first DOHAD studies concerned the relationship between birthweight and adult 
disease, where young men whose mothers were starving in their first trimester during the 
Dutch famine of 1944-5 had significantly higher rates of obesity than men from mothers 
who did not suffer from the famine or experienced the famine during late pregnancy; it 
has been the prevailing thought that it is advantageous to the fetus to conserve resources 
that would be used for organ development as fat to help ensure survival after birth (14). 
Other early DOHAD experiments found links between low birthweight and a number of 
adult onset diseases, most notably cardiovascular and renal disease (15–18).  
Fetal Growth and Uteroplacental Vascular Remodeling 
 Normal fetal growth requires proper uteroplacental vascular angiogenesis and 
pregnancy-induced uterine spiral artery vascular remodeling (19). Several factors are 
involved in blood vessel formation, which are comprised of a consecutive process known 
as vasculogenesis and angiogenesis. Both processes are required for proper growth and 
pruning of vascular beds in the maternal uterus and fetal placenta during pregnancy. 
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Known growth factors that encourage blood vessel formation and remodeling 
(angiogenic) and the regulators of those factors (antiangiogenic) significantly affect 
uteroplacental vascular development (20). 
 Vasculogenesis and angiogenesis are both critical processes in developing blood 
vessels, but they are distinctly different: vasculogenesis creates the original blood vessels, 
while angiogenesis acts upon existing blood vessels to make more vascular structures in 
response to conditions (21). Both are necessary in the developing placenta to meet the 
increased local demand for effective transport of oxygen, nutrients, and wastes via blood 
vessels. The placenta grows rapidly but also must be able to adjust to growing and 
changing demands over the course of gestation. Without sufficient development of 
uteroplacental arteries and fetoplacental capillaries, fetal growth is restricted (22, 23).  
 Vasculogenesis is defined as the differentiation of precursor cells into endothelial 
cells to form a de novo primitive vascular network. Vasculogenesis occurs early in 
gestation in human placental villi with angiogenesis following later (24). Vasculogenesis 
occurs at the fetomaternal interface, but also causes vascular changes in the uterine basal 
arteries in the first month of pregnancy (21). Vasculogenesis has three principle steps: the 
recruitment and development of hemangioblasts, the formation of hemangioblastic cords, 
and the formation of lumens to create endothelial tubes (25). Recruitment and 
development of progenitor cells occurs primarily through vascular endothelial growth 
factor (VEGF) signaling to the VEGFR-2 receptor. Fibroblastic growth factor 2 (FGF2) 
interacting with its receptor FGFR causes vasculogenesis to form cords of 
hemangioblastic progenitor cells. In addition to the VEGFR-2 receptor, VEGF also 
4 
begins to interact with VEGFR-1 (also known as Flt1) in order to form endothelial tube 
structures, the first blood vessels (22). 
 Angiogenesis, the growth and regulation of new capillaries from pre-existing 
blood vessels, follows vasculogenesis. Angiogenesis can be classified as non-branching 
or branching angiogenesis, where either blood vessels elongate or divide into highly 
branched capillary networks. In non-branching angiogenesis, existing endothelial tubes 
created by vasculogenesis can be lengthened either at the ends of the vessels, by 
proliferation, or by incorporation. Branching angiogenesis can occur by partitioning an 
existing tube longitudinally or by sprouting new side branches from an existing tube (26). 
VEGF binds to both VEGFR-1 and VEGFR-2 in angiogenesis; following branching or 
extension, vascular growth factor angiopoeitin-1 (Ang-1) recruits pericytes for the 
establishment and maintenance of the vessel walls (27). Increasing VEGF and placental 
growth factor (PLGF) increases both vessel number through branching angiogenesis and 
vascular permeability (28, 29). A balance of branching and non-branching angiogenesis 
is required for normal uteroplacental vascular growth: too little or too much branching 
may result in aberrant uteroplacental blood flow leading to placental damage and FGR. 
Pregnancy-Induced Uterine Angiogenesis                                                         
 Uterine spiral arteries are the most angiogenic vessels in the human body. During 
human female reproductive years these vessels are grown and shed each menstrual cycle. 
In pregnancy these vessels are stimulated to dilate dramatically creating funnel-like 
structures lined by invasive placental cells, which fix into widely open lumens that are 
not responsive to vasoconstrictors, essentially taking control of blood flow to the placenta 
(19). However, new data suggest the upstream radial arteries in the muscular wall of the 
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uterus may actually regulate the volume of blood flow to the placenta, while the dilated 
spiral arteries control the rate of flow (30, 31) The importance of uterine vascular 
angiogenesis is highlighted in mice (30, 32, 33). Mice do not have spiral arteries before 
they are pregnant. Unlike human females who grow spiral arteries each month of their 
menstrual cycle, female mice only grow them during pregnancy. A mouse gestation is 
approximately 19 days long. They grow spiral arteries off of the radial arteries from days 
6-12 (33, 34). This angiogenic process followed by appropriate pruning creates 3-5 spiral 
artery branches from each radial artery in mice. It only occurs in the placental bed, which 
supports the idea that placental paracrine signaling, or an implantation wound healing 
process, is required for proper uterine angiogenesis. Notably, unlike humans, mouse 
placentas are not particularly invasive into the uterus and placental invasion does not 
appear to play a role in murine spiral artery remodeling; growth and remodeling is 
complete before the mouse placenta begins invading the uterine metrial triangle (35). A 
comparison of human and murine vascular structures is presented in Figure 1.1. 
 The mechanisms regulating murine spiral artery angiogenesis are beginning to be 
understood. It is currently thought that this process is largely dependent on the presence 
of placental implantation and activation of the maternal immune system in the metrial 
triangle (36). Specifically, maternal uterine natural killer (uNK) cell activation seems to 
play an essential role in proper spiral artery angiogenesis and uteroplacental blood flow. 
 uNK cells are abundant in the human placental bed (decidua basalis) (37). They 
are also abundant in the mouse metrial triangle (38). These specialized maternal immune 
cells in the uterus are unlike NK cells elsewhere in the body and do not attack and kill 
their targets (e.g. tumors, infections, fetal placenta). Instead, uNK cells are responsible 
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for producing vascular endothelial growth factor (VEGF), which is a key regulator of 
spiral artery angiogenesis (39, 40). 
 
Angiogenic/Anti-Angiogenic Factors: VEGF, PLGF, and sFlt1 
 A major critical molecular player in angiogenesis, vascular endothelial growth 
factor (VEGF) binds its receptor, cell-surface tyrosine kinase VEGFRs, to induce highly 
effective proliferation of endothelial cells, stimulate new blood vessel formation, and 
increase cellular permeability (41). The most abundant VEGF form, VEGF-A, is secreted 
by decidual cells containing high amounts of the progesterone receptor (PR). Ovarian 
steroid secretion activates PR and plays an important part in decidua formation early in 
pregnancy. In turn, VEGF-A binds VEGFR2 to signal a number or blood vessel 
proliferative and permeability signals; this binding scenario is particularly crucial in 
uterine angiogenesis and successful implantation (42). VEGFR2 shares many of the same 
signaling pathways as Ang II type I receptors, using phospholipase C production of 
Figure 1.1. Uteroplacental arteries in human and mouse undergo angiogenesis and remodeling 
during pregnancy. In humans (seen at 10 weeks on the left), the decidual spiral arteries are already in 
place before implantation, but they grow by dilating in the first trimester. The upstream radial and arcuate 
arteries also grow longer and dilate during pregnancy. Mice (multiple uteroplacental units in a single 
gestation at d16.5, near term, on the right) grow their spiral arteries de novo during pregnancy from the 
radial arteries and comprise most of the angiogenic response to placentation. Scale bar is 1.0 cm. Human 
image courtesy of the Centre for Trophoblast Research; microCT scan courtesy of Dr. Monique Rennie. 
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inositol triphosphate to stimulate protein kinase C activity and increase calcium levels 
(43). PLGF, structurally similar to VEGF, also binds VEGF receptor 1 (VEGFR-1, also 
known as Flt1). Like VEGF and Ang II, PLGF stimulates migratory and growth 
pathways via MAPK, but does not use PLC in order to activate those functions (44). 
 Soluble fms-like tyrosine kinase-1 (sFlt1), a splice variant of VEGFR-1/Flt1, is an 
antiangiogenic factor. sFlt1 has been observed at high levels in women with 
preeclampsia, even very early in pregnancy (45). Similar to Flt1, but without the 
cytoplasmic and transmembrane domains, sFlt1 binds free VEGF and PLGF, decreasing 
their efficacy on endothelial vascular formation and remodeling (10, 46). sFlt1 is 
suspected to be sensitive to eNOS activity: the absence of eNOS may prevent sFlt1 from 
forming entirely (47). This sensitivity to oxygen species may also support the claim that 
sFlt1 is released from the placenta in response to hypoxic conditions (48). By 
sequestering angiogenic factors VEGF and PLGF, sFlt1 inhibits proper uteroplacental 
vascular development. 
Immune Responses and uNKs 
 Another piece of the FGR pathology puzzle surrounding vascular growth involves 
the multitude of immune and antibody responses which have a significant effect on 
growth and proliferation pathway signaling. Produced by CD4+ T cells, CD8+ T cells, 
and other immune and allergy response cells, cytokines can largely be divided into two 
families: type 1 (Th1-like), which favor immune response, and type 2 (Th2-like), which 
exhibit an antibody response. Type 1 cytokines include IFN-γ, TFNα, and 
interleukin(IL)-2 and 12, while the Type 2 family includes IL-4, IL-10, and TGF-β (49–
51). Historically, type 1 cytokines have been regarded as detrimental to gestation and that 
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Th1 immunity to trophoblast cells results in loss of pregnancy, where a higher ratio of 
type 2 cytokines and Th2 trophoblastic immunity is associated with successful pregnancy 
(52–54). Cytokines help maintain a valuable balance in inflammatory reactions and cell 
survival, remodeling spiral arteries through both cell survival and apoptotic signals (55). 
 Some recent research argues that the Th1/Th2 ratio is limiting in terms of 
pregnancy prognosis, because it does not take into account the action of uNK cells (56). 
uNKs play a number of roles in the vascular growth of the early placenta, from producing 
growth factors to disrupting vascular smooth muscle cells, both actions critical to spiral 
artery remodeling (57). uNKs produce VEGF and Ang-1 early in pregnancy. The levels 
of these growth factors taper off by the end of the first trimester in humans (39). This 
agrees with an early activation of uNKs seen in mice, with a switching from an inactive-
to-active state happening between GD6.5 and 8.5 in normal murine pregnancy, and uNKs 
predominantly conjugating with Th2-type CD8+ immune cells, indicating early gestation 
as a critical time for leukocyte interactions and immune regulation (58). uNK cells are 
extremely prevalent in early gestation, with 65-70% of the total lymphoid cell population 
represented by uNKs; this number decreases by mid-gestation and by term, they are 
completely absent (37, 59).  
 Although our knowledge of the pathogenesis of fetal growth restriction is 
incomplete, the growing evidence indicates that a delicate balance between angiogenic 
and antiangiogenic factors must be maintained to provide both ample and correctly 
remodeled uteroplacental blood vessels that meet fetal demands yet do not exceed 
mother’s ability to supply. Understanding these molecular influences on placental 
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structural development will allow us to develop better preventative and treatment 
measures to protect mother’s health and the fetus’ development to birth and beyond. 
Fetal Sex Effects 
 A lingering question in uteroplacental biology is whether fetal sex may play a role 
in this process. Again, the mouse serves as an excellent model because each gestation 
produces multiple pups (usually 8-12/litter) and a mixture of fetal sexes that may be 
correlated with their corresponding uteroplacental vascular architecture. Fetal sex is 
thought to be an important covariate because outcomes for males in cases of placental 
insufficiency are much worse than their female siblings—in animal models and in 
humans (60–63). Males are more likely to be negatively impacted in utero by detrimental 
effects like maternal smoking and malnutrition (64, 65). They are more likely to suffer 
from developmental programming of adult onset diseases like cardiovascular disease and 
they have a shortened lifespan compared to FGR females (15, 16, 66–69).  
 Male offspring have a higher birthweight relative to placental weight (reduced 
fetal:placental ratio) than matched female controls, which suggests males may sacrifice 
placental development in favor of fetal development (63). Since the placenta is the bridge 
between maternal supply and fetal demand, sacrificing infrastructure in favor of short-
term weight gains turns out to be a “dangerous” approach. The molecular mechanisms 
behind these observed effects and the degree to which male fetal sex affects 
uteroplacental vasculature have not been studied.  
Angiotensinogen and Placental Insufficiency                                                              
 Angiotensinogen (AGT), a member of the serpin (serine protease inhibitor) 
protein family, is the precursor and rate limiting substrate. Unlike many members of this 
10 
family, angiotensinogen does not inhibit serine proteolytic activity (70). AGT is primarily 
produced and released into plasma circulation by hepatocytes and is principally cleaved 
by enzymes in the kidney or lung to achieve a functional form (71). Angiotensinogen is 
comprised of a 453-amino acid chain, which is first cleaved by renin in response to 
decreased sodium concentration or blood pressure. This produces a 10-amino acid chain, 
angiotensin I (Ang I). Two terminal residues are cleaved from Ang I by angiotensin-
converting enzyme (ACE) to create the 8-amino acid long functional form of 
angiotensinogen, angiotensin II (Ang II) (72). Ang I may be additionally cleaved by 
chymase, a serine protease produced by placental villous syncytiotrophoblasts, and 
thereby may also contribute to increased Ang II levels (73). Ang II affects both renal 
function and blood pressure by stimulating both short and long-term vascular responses 
(74, 75). A summary of this process is illustrated in Figure 1.2. 
 Ang II type-I (AT1) receptors are G-protein coupled receptors that control blood 
pressure and volume by producing more vascular smooth muscle cells, inducing their 
Figure 1.2. Systemic and tissue-specific renin-angiotensin systems. 
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contraction, and decreasing renal blood flow (76). AT1 achieves this effect by stimulating 
phospholipase C (PLC), sodium-hydrogen antiporters, and water reabsorption. The 
primary role of PLC is hydrolyzing phosphatidylinositol 4,5-bisphosphate (IP2) to form 
inositol trisphosphate (IP3), which increases cellular concentrations of calcium. Calcium 
is crucial to vascular smooth muscle cell proliferation and contraction, the latter of which 
causes vasoconstriction by causing smooth muscle cells to contract around blood vessels 
(77). Via the formation of IP3, PLC also participates in the activation of protein kinase C 
(PKC), a phosphorylation cascade member responsible for activating transcription, 
permeability, and further cellular proliferation vital to vascular development (78). Other 
downstream effects of AT1 signaling include formation of reactive oxygen species (ROS) 
that can activate the mitogen-activated protein kinases (MAPK) to uncouple endothelial 
nitric oxide synthase (eNOS), a protein that participates in vasodilation as well as cell 
permeability (47, 79). Notably, angiotensin receptor 2 (AT2) is not highly expressed in 
the placenta, but is increased in the fetal kidney (73). It is possible that the observed 
increase of Ang II in growth-restricted pregnancies could therefore be linked to later 
onset adult renal dysfunction in FGR offspring.                                                   
 Although Ang II is required for blood vessel growth and remodeling, excessive 
Ang II levels have a negative effect on placental development. A mutation in the human 
angiotensinogen promoter A(-6) is known to cause a 20% increase in circulating AGT 
levels. An elevation in AGT levels would cause similarly increased Ang II, and therefore, 
abnormal remodeling effects (80, 81). High calcium levels produced by Ang II 
stimulation of IP3 activity can also cause extreme smooth muscle cell contraction around 
blood vessels, leading to detrimental vasoconstriction (77). High Ang II concentrations 
12 
may negatively affect blood vessel growth by competitively inhibiting the angiopoietin 
receptor TIE-2, which acts as a critical receptor tyrosine kinase in blood vessel 
proliferation signaling pathways for vascular maturation in the endometrium (82). 
 Ang II can stimulate vascular remodeling through additional angiogenic growth-
related receptors, primarily by transactivation through AT1. One of these, epithelial 
growth factor receptor (EGFR), regulates migration and hypertrophy of vascular smooth 
muscle cells when AT1 is bound to Ang II. EGFR has been reported to require AT1 
receptor phosphorylation for activation for some functions (83). Ang II also stimulates 
the platelet-derived growth factor receptor (PDGFR) and insulin-like growth factor-1 
receptor (IGF-1R) through transactivation by the AT1 receptor (84). PDGFR and IGF-1R 
both stimulate downstream ERK (a member of the MAPK cascade family) to induce 
fibrosis and hypertrophy, though the exact mechanism by which Ang II induces this 
action is unknown (85). Fibroblastic growth factor also regulates angiogenic changes, but 
it functions through a distinct MAPK pathway (85). 
Maternal Risk Factors for Placental Insufficiency and Variant AGT Expression 
 Several influences have been previously identified as maternal risk factors for 
placental insufficiency: diet and BMI (86–88), altitude and environmental quality (89, 
90), sick maternal vessels and failed maternal response (91–93), but we have focused on 
a genetic cause: an increase in maternal angiotensinogen. Placental insufficiency has been 
associated with a common variant of angiotensinogen, a substitution at angiotensinogen 
residue 235 methionine (M235) to threonine (T235); this mutation, which is tightly 
linked to a substitution of an adenine for a guanine in the angiotensinogen promoter 
region (G(-6)A), causes a 20% elevation in expression of angiotensinogen and, in turn, 
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angiotensin II (94, 95). M235 is considered a “protective” state. About 70% of the 
Caucasian population carries the protective M235 allele, while only about 2% of Central 
Africans and 15% of Asians do (96). T235 has specifically been cited as a genetic cause 
of placental insufficiency due to its reducing effect on the efficacy and number of uterine 
spiral arteries and increase in maternal hypertension (97, 98).  
Working Hypothesis 
 We hypothesize that placental insufficiency leading to fetal growth restriction is a 
multifactorial disease process involving both maternal and fetal risk factors in mice. A 











Figure 1.3. Maternal AGT genotype and fetal sex effects on angiogenic levels. 
Mouse Model of Elevated Maternal Angiotensinogen Expression 
 To study the effects of elevated maternal AGT expression on uterine spiral artery 
angiogenesis and fetoplacental outcomes, we have studied a commercially available gene 
titration transgenic (TG) mouse model that has three copies of the mouse angiotensinogen 
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(AGT) gene in a C57BL/6J background (99, 100). The extra copy of the murine AGT 
gene leads to a 1.2-fold increase in circulating AGT compared with C57BL/6J wild-type 
(WT) two copy controls. This variant was made to mimic the common human AGT 
promoter variant (A-6G) associated with preeclampsia, FGR, and abnormal uterine spiral 
artery remodeling (80, 99, 101). This “physiologic” 20% increase in circulating AGT is 
associated with increased levels of sFlt1, which is a decoy receptor for VEGF and acts as 
an antiangiogenic sequestration mechanism effectively decreasing available VEGF and 
blocking angiogenesis (42). 
 A relatively early observation by our group leading to our working hypothesis 
was that pups from TG dams were growth restricted at both mouse GD16 (near-term; 
mouse gestation is 19 days) and at birth (Figure 1.4). 
 Because this mouse model had FGR, like human pregnancies with this AGT 
genotype, we decided to address three questions for this doctoral thesis. First, what is the 
impact of the maternal AGT genotype on pregnancy, including the effects on maternal 
Figure 1.4. Relative fetal and birthweights of WT and TG dams. Males from TG dams are 
smaller than WT controls at day 16 gestation and birth, females only smaller at birth. 
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blood pressure, kidney function, uterine spiral artery growth, uteroplacental blood flow, 
placental damage, and fetal growth? Second, are there relationships between fetal sex and 
uteroplacental vascular growth mediators such as uNK activity, maternal spiral artery 
growth, placental vascular growth, placental transcriptomics, and placental nutrient 
delivery? Finally, do FGR progeny from TG dams show signs of developmental 
programming of adult onset disease, specifically cardiovascular disease (as seen in other 
models (102-105)), and what is the mechanism?  
 

















Vascular Endothelial Growth Factor Gene Delivery to  
Uterine Spiral Arteries Rescues Pregnancy-induced Angiogenesis and Prevents 
Fetal Growth Restriction in Transgenic Mouse Model of Placental Insufficiency 
 
Abstract 
 Pregnancy complications like gestational hypertension and fetal growth restriction 
are common and associated with increased maternal and neonatal morbidity and 
mortality. The causes are multifactorial, but abnormal uterine spiral artery remodeling 
and aberrant blood flow to the placenta are thought to be significant contributors. Spiral 
arteries undergo a monthly angiogenic process in menstruating women, but they are 
grown de novo in mice for the purpose of mediating blood flow to the fetal-placental unit. 
The molecular mechanisms regulating this process are not well understood, but mediators 
like vascular endothelial growth factor (VEGF), soluble fms-like tyrosine kinase-1 (sflt-
1), and angiotensin II may play important roles. To better understand the relationship 
between VEGF, sflt-1, angiotensin II, and pregnancy outcomes, we used ultrasound-
mediated microbubble conjugated VEGF gene delivery to target uterine endothelial cells 
in a previously characterized transgenic (TG) mouse model expressing 1.2-fold more 
angiotensinogen (AGT) than wild-type female controls. Luciferase gene transfer served 
as a “sham” negative control. We observed: 1) An isolated 20% increase in maternal 
AGT expression in TG dams is sufficient to cause increased angiotensin II production, 
maternal gestational hypertension, and fetal growth restriction; 2) TG dams have a 
reduced VEGF/sflt-1 ratio; 3) uterine spiral artery angiogenesis is reduced and blood flow 
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to the placenta is abnormal with signs of placental damage; 4) VEGF gene delivery to 
uterine blood vessels before mating leads to increased VEGF endothelial expression 
during early gestation (days 3-7.5), which rescues spiral artery angiogenesis and prevents 
fetal growth restriction. We conclude the AGT/VEGF axis plays a key role in regulating 
uterine angiogenesis and blood flow. 
 
Introduction  
  Investigators use the term “placental insufficiency” to describe abnormal 
uteroplacental nutrient transport, placental damage, and associated pregnancy 
complications like gestational hypertension (preeclampsia), fetal growth restriction 
(FGR), and developmental programming effects (1-4). Although the underlying causes of 
placental insufficiency remain poorly understood, abnormal pregnancy-induced uterine 
spiral artery remodeling is one well-accepted mechanism (5-11).  
Pregnancy-induced changes in uterine spiral artery remodeling may be recognized 
as early as the first trimester of pregnancy (7) with significant variation among women 
reported at term (6). The cause of this variation is uncertain, but it may begin with an 
imbalance in maternal angiogenic factors (1, 2, 12-15), shallow placental invasion (9), or 
both (16). Multiple studies support the hypothesis that angiogenic factors like vascular 
endothelial growth factor (VEGF) are essential for normal spiral artery growth and 
dilation during pregnancy (14, 15). Moreover, women with placental insufficiency are 
more likely to show abnormally increased placental production of the soluble VEGF 
receptor (sflt-1), which may inhibit VEGF activity (1, 2). The reason that human 
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placentas release more sflt-1 in pregnancies complicated by preeclampsia is not entirely 
clear, but the placenta is thought to be the primary source (2).  
We hypothesize that elevated maternal angiotensin II activity may play a role in 
stimulating sflt-1 production during pregnancy and inhibiting normal spiral artery 
remodeling. Molecular variants of the maternal angiotensinogen (AGT) gene that cause 
increased angiotensin II availability are associated with preeclampsia and FGR (17-22). 
Similarly, maternal auto-antibodies that activate the angiotensin II type 1 (AT1) receptor 
are also at increased risk for preeclampsia and fundamental alterations in human 
uteroplacental vasculature (23). We suspect this may be because angiotensin II directly 
affects spiral artery remodeling (7, 24), or indirectly inhibits pregnancy-induced spiral 
artery growth by stimulating placental sflt-1 production (25).  
 To isolate the effects of elevated maternal angiotensin II production on sflt-1 
production, spiral artery remodeling, and uteroplacental blood flow, we studied a gene-
titration transgenic (TG) mouse model (26). This TG model has three copies of the 
murine AGT gene, which simulate the 20% increase in maternal AGT expression 
observed in women homozygous for the AGT A(-6)G promoter variant associated with 
preeclampsia and FGR (17, 22). In TG males, this construct leads to hypertension (26). In 
TG females, we have shown that they do not expand their blood volume during 
pregnancy (27), similar to women with preeclampsia (28). Unlike other TG models of 
placental insufficiency, which use genetic knockouts (29), or use over-expressed human 
genes (30), this 3-copy gene-titration model employs mouse AGT expressed at 
physiologic levels, which may more accurately reflect the underlying pathophysiology of 
placental insufficiency in women. 
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 To better understand the relationship between VEGF, sflt-1, angiotensin II, and 
pregnancy outcomes, we used ultrasound-mediated microbubble conjugated VEGF or 
firefly Luciferase gene delivery to target uterine endothelial cells as previously described 
by our group to delivery VEGF to ischemic limbs in mice (31).  
 
Methods  
Murine Angiotensinogen Gene Titration Transgenic Model: Commercially available 3-
copy transgenic (TG) mice (B6.129P2-Tg (AGTdup) 1Unc/J; The Jackson Laboratory, 
Bar Harbor, Maine) were backcrossed into C57BL/6J wild-type (WT controls) for at least 
ten generations using an IACUC approved protocol (eIACUC IS080). To control for 
potential “generational effects,” all TG females in this study were “de novo” from WT 
dams mated with TG males. Mice were genotyped using a published PCR-based protocol 
(32) targeting the mouse AGT allele D8MIT56 (rs264414580). Systemic AGT expression 
was approximated by quantitative real-time RT-PCR using cDNA from fresh livers as 
described (26) and all experiments were performed in triplicate normalized to β-actin. 
Timed matings were performed and checked for vaginal plugs, which we designated as 
embryonic day 0.5 (33), with delivery confirmed at e19.5.  
Maternal Tissue-Specific Angiotensin II Measurements: Ang II peptide with and without 
C-terminal [13C15N] stable isotope-labeling was synthesized (Thermo Fisher Scientific, 
Waltham, MA) as a control for LC-SRM analysis by the Pacific Northwest National 
Laboratory. Virgin and maternal kidney and uterine metrial triangle (e10.5) angiotensin II 
levels from TG and WT mice were measured using extracts that were spiked with 100 
fmol heavy-isotope labeled Ang II, then loaded onto a reverse-phase C18 column on a 
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Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA) for Ang II peptide 
enrichment. All sample fractions were analyzed using a nanoACQUITY UPLC system 
coupled online to a TSQ Vantage triple quadrupole mass spectrometer. The light-to-heavy 
peak area ratio (L/H) of the most abundant transition (349.52/371.20 and 352.86/371.20) 
was used for quantification of endogenous Ang II in each sample.  
Maternal Serum sflt-1 Measurements: Maternal serum sflt-1 levels were measured using 
published protocols (29) and a commercially available ELISA (R&D Systems, 
Minneapolis, MN). Measurements were performed in triplicate from four-six animals 
from separate litters per group. Data were reported in pg /ml within the dynamic range of 
the assay compared with kit controls.  
Mean Arterial Blood Pressure by Radio-Telemetry: Adult (11-13 weeks) virgin female 
mice were subcutaneously implanted with TA11PA-C10 radio transmitters (Data 
Sciences International, St. Paul, MN) catheterized into the common carotid artery. 
Following one week of recovery, virgin baseline mean arterial pressure (MAP) was 
reported as the continuous average over three days. Six WT and six TG dams were then 
mated with WT males and MAP was recorded from day 2.5 to delivery (day 19.5).  
Renal Function and Glomerular Electron Microscopy: Virgin mice were trained in 
metabolic cages for ten days. Virgin blood samples (50ul) and 24 hour urine collections 
were then obtained for three days before timed mating. These pregnant mice were then 
housed in separate metabolic cages from day 5.5 to delivery. Blood samples (50 ul) and 
24 hour urine collections were taken at day 10.5 and day 18.5 for analysis. All e18.5 
pregnant females were euthanized and a portion of their kidneys were fixed in 2.5% 
glutaraldehyde for electron microscopy and examined for glomerular endotheliosis (34). 
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Urinary albumin was measured using a mouse specific ELISA kit (EXOCELL, Inc). 
Urinary and serum creatinine levels were measured by HPLC (35). 24 hour urinary 
albumin secretion was reported relative to urinary creatinine (ug/mg/day). Creatinine 
clearance was calculated as the concentration of urinary creatinine (mg/dl) x urine flow 
(ml/min) /plasma creatinine (mg/dl) to yield CrCl in mls/minute with an expected range 
of 0.125-0.250 for virgin and pregnant mice, respectively. Data were reported from virgin 
and day 18.5 WT and TG mice (n=6 animals per group. 
Contrast-Enhanced Three-Dimensional MicroCT Imaging of Spiral Arteries: Four WT 
and four TG litters at day 16.5 were tested using published methods (38). In brief, 
pregnant mice were anesthetized with isoflurane and heparinized (0.05 ml at 100 IU/ml). 
The abdomen was opened and a catheter was introduced into the descending aorta. An 
infusion pump was used to slowly perfuse the lower body vasculature with heparinized 
xylocaine (0.05 ml heparin at 100IU/ml in 2% xylocaine) to clear the vasculature of 
blood; then yellow contrast agent (Microfil HV-122, Flow Tech Inc., Carver, MA) was 
infused until it filled the exposed uteroplacental arterial circulations (38). After infusion, 
the system was tied off; the uterus was removed, fixed in formalin, and mounted in 
agarose for micro-CT scanning. 3-dimensional datasets were acquired using a Quantum 
FX micro-CT scanner (Caliper Life Sciences). Vascular surface renderings were 
generated using the Amira software package (Visage Imaging, San Diego, California) and 
three representative uteroplacental units from each litter were used to measure the 
number, length, and coiling of the spiral arteries and central canals. Data were reported as 
the average per litter to generate a mean +/- SEM for each group.  
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Modeling Uteroplacental Blood Flow with Spiral Artery Architecture: Quantitative 
structural data was used to parameterize two computational models of uterine 
hemodynamics at d16.5. The first model represented the uterine vasculature from the 
uterine artery to the level of the labyrinth, as resistance vessels acting in series and 
parallel. The model incorporated spiral artery number, length, lumen diameters, and 
dimensions of the uterine artery, radial arteries and canals as described (38). The 
resistance of each individual vessel was defined using Poiseuille’s Law (R=8L/r4, 
where =3.36x10-3 Pa.s is the viscosity of blood, L is vessel length and r is vessel radius). 
The conductivity of blood into the labyrinth was defined as a function of capillary density 
from stereology and blood flow in the labyrinth was modelled as a porous medium. The 
second model used 3D segmentations of the vascular tree in individual WT and TG dams 
to define a vascular geometry for from the uterine artery to the labyrinth, with the 
vasculature truncated at the first branch of the labyrinth capillaries with diameter < 300 
m as labyrinth capillaries become indistinguishable from one another in imaging beyond 
this level. Blood flow in the 3D model was simulated using incompressible Navier-
Stokes equations using ANSYS-CFX (Ansys Inc., Version 17.2) at the walls of the 
arteries no-slip boundary conditions were applied. Blood pressure at the uterine artery 
was predicted and compared with collected telemetry data described above. Distribution 
of blood flow across models was also compared to mean empirically collected 
microbubble ultrasound measurements of uteroplacental blood flow. 
Uteroplacental Blood Flow by Microbubble-Enhanced Ultrasound: Uteroplacental blood 
flow was measured at day 16.5 in ten WT and six TG virgin females after timed mating 
using published methods by our group (36, 37). Briefly, sterile lipid microbubbles (5% 
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Definity [Lantheus Medical Imaging, Billerica, MA] dissolved in 0.9% saline) were 
continuously infused into the jugular vein. Data for each placenta were acquired using a 
Sequoia 512 ultrasound device (Siemens Medical Systems, Mountain View, CA) 
equipped with a linear-array (15L8) transducer. Flow rates and volumes were determined 
by microbubble destruction followed by replenishment kinetics. The acoustic beam was 
centered over the pelvis and the microbubbles within the beam path were destroyed by a 
brief (2 second) acoustic burst (1.9 mechanical index). Vascular perfusion was then 
estimated for the region of interest (ROI: i.e. uterine wall or placenta) by fitting 
replenishment data to Intensity = A(1-eβτ) where the re-entry rate constant (β) reflects the 
flux rate and is proportional to vascular conductance; and, the video intensity plateau (A) 
represents microvascular blood volume. Total microvascular blood flow was calculated 
as the product of A and β. Spiral artery transit times were calculated from the time they 
reappeared in the placenta relative to the uterine wall. 
Umbilical Cord Artery Doppler: Timed gestations were used to measure fetal umbilical 
artery peak velocity at e16.5 by Doppler ultrasound using a Vevo 660 (Visualsonics 
[SonoSite, Inc.], Toronto, Canada) in anesthetized pregnant mice (n=4 WT and n=4 TG 
dams; testing three pups per litter). Absent end-diastolic flow may be normally observed 
in WT pregnancies before day 15.5 (33), therefore all gestational day 16.5 results were 
restricted to the eight deliveries confirmed at e19.5. Waveforms were analyzed while 
blinded to maternal genotype and reported as +/- absent end-diastolic flow for each fetus 
(39). 
Placental sflt-1, Heat Shock Protein 70 Expression, and Ultrastructure: Whole placentas 
dissected from the uterine wall were trimmed from four WT and four TG dams at day 
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18.5. Three placentas per litter were selected from both uterine horns for total protein 
extraction and two placentas from distal horns per litter were fixed in 2.5% 
glutaraldehyde for electron microscopy to evaluate for ultrastructural features of placental 
damage (40). Total placental protein was quantitated by routine BCA. Sflt-1 as measured 
as described above and reported as ng/mg total protein; heat shock protein 70 (HSP70) 
expression was assayed by Western blot (41) and measured by densitometry. Results 
were reported as the average per litter +/- SEM per group.  
Microbubble VEGF and Luciferase Conjugated Gene Delivery to Uterine Vasculature: 
VEGF/luciferase plasmid cDNA charge-coupled to microbubbles were injected into the 
maternal circulation and targeted to regional endothelial cells as previously described by 
our group (31). Briefly, 1 x109 microbubbles coupled to 500 ug of cDNA were infused 
into the jugular vein. The uterus was visualized by ultrasound and pulsed at 0.6 MPa 
(Sonos 5500, Philips, MA) specifically in the uterine plane, which was highlighted by 
also injecting non-conjugated bubbles via catheter into the uterus. Transfected 
nulligravida TG and WT mice (six per group) were then mated with WT males and dated 
from the time of vaginal plug noting the number of days post-transfection. Mice were 
reliably plugged within 48 hours of transfection and similar to prior studies in male mice 
(31), pilot studies showed that luciferase/VEGF expression peaked at 3 days post 
transfection and persisted for 7-10 days in virgin uteri used to establish time course.  
Statistical Analysis: Continuous data were analyzed using RS/1 software (Domain 
Manufacturing Corp). Groups were compared using the Kruskal-Wallis one-way 
ANOVA, or Mann-Whitney U test with post-hoc corrections. End-diastolic arterial blood 
flow waveforms (yes or no) in WT and TG litters were compared by Fisher’s exact test.  
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Results 
Elevated Maternal AGT Expression Leads to Hypertension and Fetal Growth Restriction 
 The genetic difference between TG and WT dams was the presence of the 
AGTdup construct in an otherwise shared black 6 background (3-copies versus 2-copies 
of the murine AGT gene, respectively). Breeding females were all 11-13 weeks old, 
nulligravida, and they were all bred with WT males. TG females expressed 
approximately 20% more AGT than WT controls (Figure 2.1A), similar to prior reports 
(26). Tissue-specific angiotensin II levels in the maternal kidneys and maternal metrial 
triangles were also increased in TG dams with 5-fold differences in the maternal kidneys 
and 2-fold differences in the uterine metrial triangles (Figure 2.1B-D).  
 TG dams had significantly elevated serum sflt-1 levels (Figure 2.1E), but this 
increase (30 ng/ml) was insufficient to cause glomerular endotheliosis or proteinuria 
(data not shown). WT controls increased their creatinine clearance by 20% by term (0.25 
ml/min versus 0.20 ml/min in virgin females) while TG dams did not (0.15 mls/min) 
similar to women with preeclampsia (42). Total placental sflt-1 protein levels were 10% 
greater in TG dams compared with controls (62 +/- 13 ng/mg versus 56 +/- 4 ng/mg, 
respectively, although this difference did not achieve statistical significance).  
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Figure 2.1. Elevated systemic maternal AGT expression leads to increased angiotensin II, 
elevated sflt-1, and maternal hypertension. A) AGTdup 3-copy transgenic (TG) mice backcrossed 
into C57BL/6J wild-type (WT) for more than ten generations show slightly increased liver AGT 
expression compared with controls (~20% increase). B) Microdissection of maternal uterine placental 
bed tissue (metrial triangle) away from placenta and fetus at mid-gestation for angiotensin II 
measurements by HPLC/MS (C) shows increased angiotensin II in metrial tissue and maternal 
kidneys of TG dams compared with WT controls (D). Maternal sflt-1 levels are elevated (E) and 
maternal blood pressure is elevated in TG dams. *P<0.05; **P<0.01.  
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 Radio-telemetry revealed no difference in mean arterial pressure (MAP) between 
virgin TG and WT females, but during pregnancy TG dams failed to undergo normal 
drops in blood pressure, unlike WT controls (Figure 2.1F). Relatively elevated MAP 
could be reliably detected as early as e3.5 and persisted through gestation.  
Fetal Growth Restriction 
 Fetal weights at day 16 were lower in TG dams compared with age-matched WT 
controls (Table 2.1). Placental weight was not decreased in TG dams (Table 2.1); 
therefore, the overall placental efficiency (fetal weight/placental weight) was reduced in 
their progeny. Newborn pups from TG dams were 7-10% smaller than WT controls.  
 
Reduced Spiral Artery Angiogenesis in Transgenic Dams 
 WT and TG dams near term (day 16.5) were infused with contrast agent as 
described (38) to visualize and measure the maternal uteroplacental vascular anatomy. 
Three-dimensional surface renderings revealed a complex network of coiled spiral 
arteries in WT dams (4-6 per placental unit) that merged into larger central canals feeding 
Table 2.1. Fetal Growth Restriction in Maternal Angiotensinogen Overexpression Model 
  
   Wild-Type (WT) (n=17) Transgenic (TG) (n=15) P-value 
  
Litter size  8.1 +/- 0.16 (range 7-9) 6.5 +/- 0.75 (range 3-10) P=0.29 
  
Day 16.5 Progeny  
Fetal Weight  0.51 grams +/- 0.01 0.45 grams +/- 0.02 P=0.01 
  
Placental Weight  0.088 grams +/- 0.002 0.095 grams +/- 0.002 P=0.03 
  
Fwt/PLwt  5.8 +/- 0.16  4.8 +/- 0.28  P=0.01 
  
Birthweight*   1.43 +/- 0.03  1.26 +/- 0.04  P=0.01 
  
Preterm data are based on weights at day 16.5 after vaginal plug for n=7 WT and n=9 TG litters. 
* Birthweight data are based on post-delivery day 1 for n=10 WT and n=6 TG litters. 
Placental efficiency was defined as fetal weight (Fwt) divided by placental weight (PLwt).  
Data are means +/- standard error (SEM). P-values based on nonparametric Mann-Whitney U-test. 
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the placental labyrinth (Figure 2.2A). In contrast, the number of spiral arteries in TG 
dams was reduced by approximately 30% (Figure 2.2B, C); and, the length and number 
of spiral artery coils/mm were also reduced (Figure 2.2D). However, the diameter of 
central canals downstream to the spiral arteries were not significantly different between 
WT and TG dams (0.36+/-0.2 mm, 0.41+/-0.3 mm, p=0.23, respectively).  
Hemodynamic Modeling using Blood Pressure and Uterine Vascular Architecture  
 We employed the mean maternal blood pressure at day 16.5 from each group and 
the mean uteroplacental arterial architecture derived from 3DmicroCT data from the 
uterine artery to the level of the placental labyrinth as resistance vessels acting in series 
and parallel. The resistance of each vessel type (uterine, radials, spiral arteries, labyrinth) 
was calculated using Poiseuille’s Law and vessel length, radius, and numbers expected 
for WT mice were additionally compared with published values by Rennie et al. (38) for 
comparison. Modeling studies suggested that the structure of the spiral arteries should be 
the major driver of differences between WT and TG hemodynamics. Spiral artery 
structure played a dominant role in TG hemodynamics, but a more minor role in the WT 
group. In the WT group, the greater number of spiral arteries feeding each placenta 
effectively decreased flow resistance by 4.6 times compared with the TG group. Because 
resistance to flow was low in the WT group, structural variability in other levels of the 
uteroplacental vascular tree exerted greater effects, which should translate into greater 
variability in blood flow transit times in WT mice compared with TG dams. Overall, 
including differences in blood pressure at day 16.5 (WT ~85mmHg; TG ~112 mmHg) the 
predicted transit times of a volume bolus through the WT uteroplacental arterial network 
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would be expected to be 5-8 seconds; whereas TG dams are expected to have faster and 
narrower transit times in the range of 1-2 seconds (Figure 2.2F). 
Figure 2.2. Abnormal spiral artery growth visualized by 3D microCT imaging and uteroplacental 
blood flow modeling estimates. Representative examples of iso-intensity surface renderings obtained 
from three-dimensional micro-CT imaging data collected at day 16.5 from wild-type (WT) controls (A) 
and transgenic (TG) dams (B). (C-D) Quantitative analysis of four litters per group imaging three 
implantation units/litter showed significantly more spiral arteries with more coils/mm in WT mice 
compared with TG dams. E) Average blood pressure and spiral artery architecture (diameter, length, 
branching, coiling) at day 16.5 for each maternal genotype was used to model the resistance and expected 
flow through these vessels, which suggested a slower flow rate through WT units (F) related to more spiral 
artery branching and lower mean blood pressure compared with TG dams. Scale bars are 1.0 mm.  
** P<0.01. 
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Abnormal Uteroplacental Blood Flow in TG Mice 
 We used contrast-enhanced ultrasound to quantify blood flow velocities and 
volumes in TG dams and WT controls. We have previously used this microbubble 
enhanced imaging method to measure uteroplacental blood flow in non-human primates 
(36) and in women during the first trimester of pregnancy (37). Others have used it to 
measure uteroplacental blood flow in rats (43). Measurements are based on regional 
reappearance kinetics of microbubbles after targeted elimination by an ultrasound 
induced cavitation. In WT dams, the microbubbles reappeared rapidly in the uterine wall; 
transit time slowed down as they coiled through the spiral arteries and then they slowly 
filled the placental labyrinth (Figure 2.3A). In contrast, placentas from TG dams filled 
rapidly with similar reappearance kinetics to filling of the uterine wall (Figures 2.3B, C). 
Placental filling transit times in TG dams was within 2 seconds of cavitation, indicative 
of faster arterial conductance; whereas WT mice required 4-8 seconds (Figure 2.3D). 
These measurements were surprisingly similar to those predicted by our hemodynamic 
modeling based solely on blood pressure and uteroplacental architecture (Figure 2.2F). 
Quantitative analysis of total placental microvascular blood flow was not statistically 
significantly different between WT and TG dams at day 16.5 (Figure 2.3E). Since transit 
times through the TG circuit are 2-4 times faster than WT dams, this implies that smaller 
bolus volumes are transiting faster in TG dams. That is to say, TG dams had faster flow 







Figure 2.3. Microbubble-enhanced ultrasound measures uteroplacental blood flow. A) Microbubble 
reappearance kinetics in the uterine wall are fast (digitally coded as red), which then slow as the bubbles 
wind their way through the uterine spiral arteries (asterisk), leading to relatively slower filling rates of the 
placental labyrinth (coded as green) in WT controls. B) In contrast, the placentas in TG dams fill very 
quickly relative to the uterine wall, with no apparent spiral artery lag time. C) Reappearance kinetics plotted 
as signal intensity relative to time (seconds) highlights the spiral artery lag time in this day 16 WT 
uteroplacental unit (arrow), which is absent in the day 16 TG dam. D) Data averaged over six litters per 
maternal genotype show reproducible lag times in WT dams (4-8 seconds), which are essentially absent in 
TG mice. E) The maternal component of placental blood flow volume is not significantly different between 
WT and TG dams. Data are mean +/- SEM of at least three implantation sites/litter. (A-B) scale bar is 2.0 
mm. * P<0.05; N.S. is not significant. 
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Placental Damage and Absent End-Diastolic Flow in TG Mice 
 Faster flow velocities may be responsible for placental damage, because the 
placentas from TG dams showed evidence of ultrastructural damage and their placentas 
expressed more heat shock protein 70 (HSP70) compared with WT controls (Figure 2.4). 
In humans, damaged small placentas are associated with umbilical cord Doppler absent 
end diastolic flow (39), which was seen in all 12 cords examined from TG dams, but 
none of the WT controls (0/12; Fishers Exact p-value<0.001).  
Figure 2.4. Placental damage and 
oxidative stress leading to absent end 
diastolic flow in fetal umbilical arteries.  
A) Representative electron microscopic 
images from WT (A) and TG (B) placental 
labyrinth at day 16.5. WT placentas have 
normal appearing cytotrophoblasts (ctb) 
with healthy-appearing microvilli (arrow). 
In contrast, placentas from TG dams show 
loss of microvilli with more microvesicles 
in the maternal blood space (asterisk) and 
electron dense whorls, known as lamellated 
lipid inclusions, or “myeloid bodies” 
(arrowheads). C) Western blot analysis for 
heat shock protein 70 (HSP70) in placental 
extracts reveals more evidence of placental 
damage in TG dams. D) Doppler ultrasound 
shows normal systolic peak flow velocity 
and diastolic flow (arrow) in the fetal 
umbilical cords of WT dams, but absent 
diastolic flow in TG pregnancies, which is a 
characteristic clinical sign of severe 
placental insufficiency (representative of 
n=4 litters/group, testing 3 units/litter). 
Scale bar is 6.0 um. **P<0.01. 
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Uterine VEGF Transfection Rescues Spiral Artery Angiogenesis and Fetal Growth 
 Uterine vascular targeted transfections we performed in WT and TG virgin mice 
using VEGF and/or firefly Luciferase plasmid conjugated to cationic microbubbles 
according to our group’s previously published methods (31). Expression time course 
studies were first performed in non-mated WT mice to confirm hVEGF165 expression in 
uterine tissues, which peaked at 3-7 days post transfection (Figure 2.5).   
 Uterine luciferase expression was monitored daily by intraperitoneal luciferin 
injection and bioluminescence (Figure 2.5 C). Ex vivo resected organs (uterus, bladder, 
liver, lungs) were also examined by bioluminescence and expression was localized in 
formalin fixed sections by immunohistochemistry as described (31). We observed strong 
Luciferase signal in the uterus and bladder, but not lung or liver and transfection 
localized to endothelial cells as expected (data not shown).  
 Transfected mice were mated with WT males and timed pregnancies (from 
vaginal plug and transfection date) were used for uteroplacental arterial 3DmicroCT 
imaging at e16.5, or allowed to deliver at term (e19.5). Notably, not all uteroplacental 
units in TG dams transfected with VEGF showed full spiral artery architectural recovery 
(Figure 2.6A), but efficiency was sufficient to increase spiral artery angiogenesis and 
rescue birthweight. Luciferase transfection (control) did not increase birthweight.   
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Figure 2.5. Microbubble Conjugated VEGF/Luciferase Plasmid DNA Transfection of Mouse Uterine 
Vasculature. (A) Working hypothesis is increased VEGF expression by uterine spiral artery endothelial 
cells will rescue the elevated angiotensin II maternal TG phenotype. B) Microbubble conjugated plasmid 
DNA was delivered to the uterine vasculature by popping the bubbles with targeted pulse delivering VEGF 
and/or luciferase to uterine endothelial cells as previously described by our group (31). C) Firefly luciferase 
reporter activity was localized and monitored in pregnant mice. Time course for uterine VEGF expression 
by delivered hVEGF plasmid (D) or endogenous murine VEGF (E) measured by qRT-PCR. Delivered 
VEGF spike correlated with endogenous VEGF expression spike in the gravid mouse uterus (n=4-6 litters 




 Transgenic mice expressing 20% more systemic AGT than C57BL/6J controls 
develop gestational hypertension and have growth restricted progeny, similar to women 
with the A(-6) promoter variant associated with preeclampsia and FGR (17, 22). These 
TG dams have characteristic features of placental insufficiency, including elevated serum 
sflt-1 and absent end-diastolic flow in fetal umbilical arteries. They have fewer and less 
Figure 2.6. Microbubble Conjugated VEGF Delivery Rescued Spiral Artery Angiogenesis and Fetal 
Birthweight. (A) Representative 3DmicroCT image of 7 uteroplacental units within a VEGF transfected 
TG gravid uterus at day 16.5. Some of the units showed normal appearing spiral artery branching, 
lengthening, and coiling (green arrow), while others di d not (grey arrow). B) Overall the number of spiral 
artery branches per unit were rescued in VEGF treated TG dams compare with untreated TG dams. C) 
Luciferase transfection did not rescue birthweight, but VEGF delivery yielded litters with birthweights very 
similar to WT controls (n=4-6 litters/group); **P<0.01. 
36 
coiled spiral arteries, which is associated with increased uteroplacental blood flow 
velocities and significant placental damage.  
Renin-Angiotensin System and Spiral Artery Remodeling 
 The systemic renin-angiotensin system (RAS) is upregulated during pregnancy 
and is known to play a major role in regulating blood pressure and blood volume (44, 27). 
Tissue-specific RAS systems, including the spiral artery RAS, are also upregulated and 
have local effects (19, 24, 27). Since AGT is at the Km of the renin-angiotensinogen 
reaction (20), abnormally elevated AGT expression is expected to lead to increased 
angiotensin II activity and potential pathology, including abnormal spiral artery 
remodeling (7, 19, 23, 24). The significance of the TG mouse model is it isolates the 
effects of elevated AGT expression. Our results demonstrate that abnormally increased 
maternal AGT expression leads to less spiral artery growth and less branching, which 
may be interpreted as abnormal pregnancy-induced remodeling (29). Elevated 
angiotensin II activity may also affect vascular tone (44), which may account for 
increased blood pressure and reduced blood volume (27) in this model.   
 Although systemic levels may not reflect local tissue-specific systems (44), it is 
reasonable to hypothesize that elevated AGT expression may abnormally stimulate 
placental sflt-1 production (25). We did observe significantly increased maternal serum 
sflt-1 levels by mid-gestation and their placentas produced slightly more sflt-1 at term. 
This increase in sflt-1 production, however, was not sufficient to cause glomerular 
damage or proteinuria (1). This may be because sflt-1 levels were about 10-fold less than 
those used to induce glomerular damage in rats (1); although they were nearly 10-fold 
more than elevated levels observed in women with preeclampsia (1). Whether circulating 
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sflt-1 levels were sufficient to sequester spiral artery VEGF (14, 15) and reduce 
pregnancy-induced spiral artery growth requires further study, but we have now shown 
that delivering VEGF to uterine endothelial cells is sufficient to rescue the phenotype in 
our mouse model.  
Abnormal Spiral Artery Remodeling, Faster Flow Velocities, and Placental Damage 
 Pregnancy-induced spiral artery growth is important. Before pregnancy, mice do 
not have spiral arteries (45), but from early to mid-gestation the spiral arteries branch and 
elongate from the uterine radial arteries into coiled conduits regulating blood flow to the 
placenta (46). This is similar to spiral artery growth and remodeling observed in women 
each month during the secretory phase of their cycle and during the early stages of 
pregnancy (45, 46). This remodeling appears to vary within and between individuals, 
which may play a role in pregnancy complication risk (6, 7), but we suspect spiral artery 
growth variation may also be involved in regulating normal uteroplacental blood flow. 
For example, our group has recently reported there is significant variance in flow rates 
(12-45 ml/min) between cotyledons within each rhesus macaque placenta tested by 
contrast-enhanced imaging (47). Perhaps differences in spiral artery length and dilation 
play a critical role in regulating the pulsatile delivery of maternal blood to the placenta. 
Perhaps a common underlying cause of placental insufficiency is a shift in this normal 
variance (6, 7).  
 Maternal blood pressure may also affect flow rates, but it is important to point out 
that uteroplacental vascular resistance is not well understood. It may be more likely that 
the proximal radial arteries, which show less branching, have smaller luminal diameters, 
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and have active smooth muscle cells, are more important regulators of driving pressure 
than spiral arteries (11, 38). Regardless, the consequence was placental damage.  
 Placental damage in our model was not caused by reduced uteroplacental blood 
flow volume, but may have been caused by the observed increased flow velocity in TG 
dams. Fewer spiral arteries in parallel under greater driving pressures would be expected 
to increase shear stress effects. The loss of trophoblast microvilli in TG dams may reflect 
this increased stress similar to what is seen in women with preeclampsia (40). Indeed, 
shear stress is proportional to the flow velocity and inversely related to vessel radius. TG 
dams have higher uteroplacental flow velocities and smaller radii due to fewer spiral 
arteries per metrial triangle. Modeling shear stress is very complicated, however, and this 
prediction may not be correct despite the surprising correlations we observed between our 
modeled transit times and empirical microbubble enhanced imaging studies. The problem 
is shear stress estimates are based on straight vessels (not coiled) and laminar flow. The 
problem becomes even more complicated when considering the turbulence in the 
placental labyrinth or intervillous space of a human.  
Placental Invasion and uNK cell Activation 
 A limitation of this study is we did not investigate the role of placental invasion or 
differences in uNK cell activation, which are known regulators of spiral artery 
angiogenesis and remodeling (48-50). Placental proximity seems to be important for 
spiral artery angiogenesis in the mouse, but invasion into the walls of these vessels is less 
important in these brief gestational periods than what seems necessary in women (45, 
46). Uterine NK cell activation plays a key role in murine spiral artery angiogenesis and 
likely plays an important role in women [our investigation into uNK cell 
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activity/maternal genotype and its role in uterine VEGF production is covered in Chapter 
3 of this doctoral thesis].  
 Nonetheless, it is important to point out that effects of placental invasion and/or 
uNK cell activation impacting spiral artery angiogenesis in TG mice would be secondary 
to the maternal AGT genotype. Elevated maternal AGT expression and metrial 
angiotensin II production seem to be sufficient to lead to be the primary cause of 
abnormal spiral artery angiogenesis, abnormal blood flow to the placenta, placental 
damage, and fetal growth restriction. This process can be essentially rescued by 
increasing VEGF expression in the uterine vascular network during early pregnancy. 
Vascular Endothelial Growth Factor and Spiral Artery Angiogenesis 
 An important strength of this study is the demonstration that plasmid-conjugated 
microbubbles may be used to target increased expression of candidate genes in 
endothelial cells during pregnancy. We have previously used this technology to increase 
VEGF expression in an ischemic limb murine model (31) and have shown that targeting 
by microbubble cavitation does not lead to hemorrhage, but it does transfect endothelial 
cells at relatively high efficiency. Expression last about 1 week post transfection, 
although luciferase activity may be detected weeks after transfection in our experience. 
This is important because uterine VEGF peaks around e5.5-6.5 in the mouse uterus 
during the early period of spiral artery angiogenesis (50) and before pruning of the 
arterial network into well-formed spiral arteries. Our data suggest that sufficiently 
available endothelial VEGF is required for normal spiral artery angiogenesis. Endothelial 
availability is essential because VEGF receptors on endothelial cells (VEGFR1) stimulate 
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different angiogenic/anti-angiogenic pathways than receptors in the vessel wall and 
surrounding decidua (VEGFR2) (51).  
 A difference in VEGF availability (intravascular/endothelial versus 
decidual/endometrial stromal) may therefore explain why artificially increasing decidual 
VEGF availability rather than restricting the increase to endothelial cells could lead to 
different outcomes in transgenic mice. For example, Fan et al (2014) showed that 
increasing VEGF expression in uterine decidual cells in transgenic mice led to poor 
pregnancy outcomes (52). Spiral artery angiogenesis studies were not performed in that 
study, but one may speculate that increased VEGFR2 stimulation may lead to excessive 
vasculogenesis and less well formed spiral arteries to provide normal blood flow to the 
placenta (blood flow studies were also not performed in that study).  
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Fetal Sex Affects Uteroplacental Angiogenesis in  
Mouse Model of Fetal Growth Restriction 
 
Abstract 
 Elevated maternal angiotensinogen (AGT) expression (20% increase in AGT 
transgenic (TG) dams vs. wild-type (WT) controls) reduces spiral artery branching and 
coiling by gestational day (GD) 16.5. The consequence is abnormal uteroplacental blood 
flow, placental damage, and fetal growth restriction that disproportionately affects male 
offspring. We hypothesized that, in addition to maternal genotype, male fetal sex will 
impact uteroplacental vascular structure, uterine natural killer cell (uNK) activity, and 
uteroplacental expression profiles affecting pregnancy-induced angiogenesis. Uteri from 
WT and TG dams were harvested during early gestation (GD6.5 and GD8.5) to measure 
uNK activity via whole mounts using fluorescent Ly49 (inactive uNKs), DBA (active 
uNKs), and CD31 (developing blood vessels) staining to examine the role of early 
angiogenesis affecting later spiral artery remodeling. At day 16.5 we measured spiral 
artery architecture by 3D microCT. We calculated placental capillary density, measured 
placental nutrient transport, and compared placental transcriptomic profiles at day 16.5. 
We observed that males from TG dams were associated with decreased maternal uNK 
activity, reduced pro-angiogenic expression in the metrial triangle, reduced angiogenesis 
at days 6.5, 8.5, and fewer spiral arteries per placental unit at day 16.5. Male placentas 
from TG dams also had reduced placental capillary density compared with their female 
siblings and WT controls. Surprisingly, transcriptomic analysis revealed upregulation of 
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nutrient transporters in male placentas from TG dams, which was confirmed by lipid and 
amino acid transport studies performed at day 16.5. We conclude that male fetal sex 
compounds the impact of maternal genetic risk in this mouse model. Our data suggest the 
mechanism may be related to less placental pro-angiogenic signaling, reduced uNK cell 




 Fetal growth restriction (FGR) is a common and potentially life-threatening 
complication, occurring in 5-10% of all human pregnancies (1). It is a multifactorial 
disorder characterized by constrained growth during pregnancy, resulting in fetal weight 
below the 10th percentile for gestational age relative to the average population (2). 
Negative health outcomes associated with FGR include increased perinatal mortality and 
a three-fold increased risk of adult onset diabetes and cardiovascular disease (3, 4). Male 
fetuses are more negatively affected by FGR than females: they are more likely to be 
stillborn, born earlier with poorer survival outcomes, and they have a greater risk for 
developmental programming of adult onset diseases (5–8).  
 Small for gestational age newborns come from small placentas with gross and 
histologic features of maternal malperfusion (placental insufficiency), including 
infarctions and accelerated villous maturation (9). Placental insufficiency implies that the 
mother or the placenta have an impaired ability to supply fetal nutrient demands (10–14). 
This may be related to insufficient maternal nutrition (e.g. low protein diet), insufficient 
delivery of nutrients (e.g. pathologic changes in the uteroplacental arterial network), 
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and/or increased fetoplacental demand (e.g. twin gestations) (4, 15–18). The reason why 
males do more poorly than female growth restricted babies is unknown, but a leading 
hypothesis is that males do not sufficiently invest maternal derived nutrients into 
placental growth compared with females (8) and/or they may have relatively increased 
metabolic demands (19).  
Maternal nutrition to the fetoplacental unit is supplied via the uteroplacental arterial 
network. Maternal uterine angiogenesis and pregnancy-induced remodeling are essential 
for a normal pregnancy outcome in both mice and humans (9, 20, 21). In humans, the 
endometrial spiral arteries grow, coil, and dilate in a process related to a combination of 
placental invasion and vascular angiogenic growth factors (e.g. placental growth factor 
[PLGF], vascular endothelial growth factor [VEGF]) (22–24). Mouse uterine arterial 
angiogenesis and vascular remodeling mimic human pregnancy-induced changes with the 
exception that in mice the uterine spiral arteries grow de novo for pregnancy (25). 
The mouse placenta is different than humans in that it is composed of a labyrinth 
of interdigitating maternal capillary-like spaces lined by placental trophoblasts encasing 
fetoplacental capillaries. In contrast, in humans, the spiral arteries open into the 
intervillous space, which then drains into the decidual veins (25). The placental bed of 
mice and humans, however, is very similar composed of decidual cells, macrophages, 
dendritic cells, and uterine natural killer cells (uNK) that are thought to play a key role in 
regulating proper spiral artery angiogenesis and remodeling during pregnancy (22–26). 
Uteroplacental angiogenic factors like VEGF are released by activated uNK cells and 
they are made by placental cells to stimulate angiogenesis in the uterus and in the 
placenta (27). Indeed, vascular growth in the both the uterus and placenta seem to rely on 
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similar angiogenic/anti-angiogenic pathways involved in vasculogenesis to grow 
capillary-like networks and angiogenesis to prune them into arteries and capillary beds 
for nutrient exchange (28, 29).  
We hypothesized that uteroplacental angiogenesis may be different in males 
compared with their female siblings. We studied a murine angiotensinogen gene titration 
over-expression model (1.2-fold wild-type levels), which was originally designed to 
mimic a common human promoter variant associated with chronic hypertension, 
pregnancy-induced hypertension, and fetal growth restriction (30, 31). Our group has 
shown that TG mice have reduced spiral artery angiogenesis, abnormal blood flow to 
their placentas, develop placental damage and FGR (see Chapter 2). This mouse model 
was selected in part because mice have multiple pups per litter and fetal sex could then be 
compared within each litter and between litters relative to maternal genotype. 
 
Methods 
Transgenic Mouse Model: Experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Oregon Health and Science University. 
Angiotensinogen (AGT) 3-copy transgenic (TG) dams (B6.129P2-Agttm1Unc/J (30)) were 
purchased from The Jackson Laboratory (Bar Harbor, Maine) and backcrossed with wild-
type (WT) C57/BL6 mice from Charles River Laboratories (Wilmington, MA) for more 
than ten generations before experimentation. Adult (11-13 weeks old) TG and WT 
females were bred with WT males and matings were timed from vaginal plug (GD0.5). 
Fetal sex (SRY) and genotype (AGTdup) were determined by PCR. Briefly, DNA from 
fetal liver tissue or adult tail snips was extracted using DNeasy (QIAgen; Valencia, CA) 
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or REDExtract-n-Amp PCR Reaction Mix (Sigma-Aldrich; St. Louis, MO), respectively. 
AGT genotype and fetal sex were determined by PCR using specific primer sets 
[Supplemental Table 3.1] that yielded products of expected size and DNA sequence. Both 
PCR reactions used the following cycling parameters: initial melting at 94C for 2 min; 
followed by 40 cycles of 94C for 20 s, 65C for 30 s, 72C for 30 s; followed by a final 
72C extension for 5 min. All samples have the endogenous AGT genetic PCR product 
(160 bp), which served as an internal positive control for the PCR reaction. WT 
genotypes had only the 160 bp band; whereas, AGT 3-copy mice (TG) showed both a 
160 bp band and a 189 bp band for the AGTdup transgene. In the SRY reaction, a 249 bp 
band indicated male fetal sex; females lacked the SRY band, but retained the WT AGT 
product. Note: only WT fetal genotypes from TG dams were used for these analyses; TG 
pups from TG dams introduced an additional potential confounder (3-copies of AGT 
gene) excluded in these analyses.  
Tissue Samples for Expression Analysis: Maternal blood, uterine decidua (metrial 
triangle), placentas, and corresponding fetal livers (to determine fetal sex and genotype 
corresponding to its placenta and maternal metrial triangle) were isolated from TG and 
WT mice (4-6 litters/group) at mid-gestation (GD12.5) and late gestation (GD16.5) for 
qRT-PCR, ELISA, HPLC, and RNASeq (GD16.5 only) experiments. Maternal blood was 
collected in heparin tubes and centrifuged and plasma banked at -80C. Maternal metrial 
triangles from the placenta bed and fetal placentas were microdissected at GD12.5 using 
a published protocol (23). Placentas at GD16.5 from TG and WT dams were flash frozen 
and RNA and protein were extracted using commercially available kits. 
46 
Three Dimensional MicroCT Measurements of Uterine Arterial Networks: TG and WT 
dams (n=4 litters each) were euthanized and perfused for microCT imaging at GD16.5 
(per vaginal plug after timed mating) as previously described by Dr. Rennie in our group 
(32). Spiral artery number, branching, and coiling in each uteroplacental unit were 
measured independently by two reviewers (MR and JH) blinded to maternal genotype 
and fetal sex. The average values from each reviewer for each uteroplacental unit were 
used to generate mean values +/- SEM per fetal sex for each litter.  
Placental Stereometry: Placentas obtained from the microCT harvest were weighed, 
measured, and paraffin-embedded for histologic analysis. Fetoplacental capillary number 
and density for each placenta was determined using a standard stereometric approach (33, 
34). Briefly, randomly oriented and sectioned placental slices (5 μm thick) were 
immunostained for CD31 to highlight endothelial cells in fetoplacental capillaries. The 
placental labyrinth within each section was outlined using Stereo Investigator and 
software (MBF Bioscience; Williston, VT). The number of capillaries within each 
placenta’s labyrinth area calculated and compared within groups (e.g. fetal sex and 
maternal genotype). 
Angiogenic/Anti-angiogenic Protein Expression Analysis: 10ug of protein from each 
sample determined by BCA (Thermo Fisher; Waltham, MA) were analyzed using 
commercially available ELISAs (R&D Systems; Minneapolis, MN) for sFlt1, VEGF, and 
PLGF according to manufacturer’s instructions. Protein expression levels in each sample 
were generated by comparison with the standard curve generated by kit internal 
standards. Each experiment was performed in triplicate and values were within the 
dynamic range of each ELISA assay.  
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Placental Nutrient Transport Assay: Placental transport of radiolabeled fatty acids and 
amino acids were measured in vivo in four TG and four WT dams at GD16.5 (near term) 
using previously described methods (35–37). Briefly, 14C-radiolabeled C-DHA (2uCi/kg) 
(lipid transport) or 14C-methylaminoisobutyric acid (MeAIB) (50 uCi/kg) (amino acid 
transport) were administered in a 100ul PBS bolus via maternal jugular catheterization. 
The mice were euthanized at 90 or 3 minutes, respectively; maternal blood, placentas, 
and fetuses were collected and solubilized with Solvable/Biosol (PerkinElmer; Waltham, 
MA) to determine radioactivity in each fraction relative to weight. Maternal-placental-
fetal unidirectional clearance (K) for each tracer was calculated by dividing fetal counts 
(N) by the area under the maternal isotope concentration curve (AUC) from time 0 to 
sacrifice (dpm*min*ul-1) multiplied by placental weight (W): K=N/[AUC*W]. 
Experiments were performed in triplicate and reported as the means per fetal sex per 
maternal genotype.  
Placental Transcriptomics: cDNA libraries were prepared from placentas known to be 
from male or female pups from TG and WT dams (representative of 4 litters per group) 
using the TruSeq RNA Sample Preparation Kit (Illumina; San Diego, CA). Poly-A 
containing mRNA was extracted using magnetic poly-T oligonucleotide containing 
beads, then fragmented and copied into first strand cDNA followed by second strand 
cDNA synthesis. cDNA fragments were ligated to adapters, purified, and enriched via 
PCR to create final cDNA libraries with hexamer barcodes to facilitate sample 
multiplexing. Purified libraries were quantified on a Bioanalyzer 2100 (Agilent; Santa 
Clara, CA) using a DNA 1000 chip and sequenced using Illumina HiSeq™ 2000. CLC-
workbench (version 9.0; CLCbio) was used for analysis on reads compiled for de novo 
48 
assembly. Differential gene expression was calculated using Empirical analysis of DGE 
in CLC-workbench, controlling FDR at 0.05. GO terms were found using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) and the GO FAT filter. 
GO-term enrichment tests were also performed (38, 39) 
qRT-PCR Validation of RNASeq: RNA from each sample was converted to cDNA using 
SuperScript III First-Strand Synthesis System and amplified using TaqMan probes (Life 
Technologies; Carlsbad, CA) to measure expression of several significant genes from key 
gene ontologies identified by RNASeq relative to Gapdh base-line expression: Fabp1, 
Fabp4, Acox2, Cox1, Cox2, Clec2d, Klrb1b [Primers in Supplemental Table 3.2]. 
Amplification was conducted using a Roche LightCycler as follows: 1 cycle at 95C for 5 
minutes, 40 cycles of 95C for 15 seconds and 65C for 60 seconds (with acquisition at 
65C). Cycle point crossings were compared with a standard curve for each marker to 
quantify the relative starting amount of mRNA expressed in each sample.  
uNK Cell Activation and Angiogenesis in Whole Mounts: Uterine natural killer cell 
activation and metrial triangle angiogenesis whole mount experiments were performed in 
collaboration with Dr. Anne Croy’s laboratory as described by their group (23, 40). 
Briefly, immunofluorescence assays were performed at GD6.5 and 8.5 using in situ 
whole mounts from TG and WT dams (4-6 litters/group). when the populations of uNK 
cells have been reported to be changing most dramatically (23). GD8.5 is also when 
vasculogenesis/angiogenesis is reportedly at its peak (40). First, the mesometrial uterine 
walls were bisected on the midsagittal line of the mesometrial-antimesometrial axis. It 
was then stained with FITC-conjugated Dolichos biflorus agglutinin (DBA) lectin 
(Vector Laboratories; Burlingame, CA), which when positive indicates activated uNK 
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cells; and PE-conjugated Ly49C/I (BD Pharmigen; Franklin Lakes, NJ), which when 
positive indicates inactive uNK cells. Anti-CD31 (Biolegend; San Diego, CA) staining 
highlighted endothelial cells in the metrial triangle to quantify blood vessel number, 
branching, and so-called “blebbing” (41) in each whole mount. The embryo was then 
digested for DNA and genotyping.  
Statistical Analysis: Fetal sex per maternal genotype was the primary variable for 
analysis using the mean from at least four litters per maternal genotype. Data were 
analyzed by two-way ANOVA with Tukey’s multiple-comparison post hoc correction.  
 
Results 
Male Fetal Sex Affects Maternal Uterine Angiogenesis in TG Dams 
 Representative 3D microCT images from males and females from WT dams and 
TG dams are shown in Figure 3.1A. Fetal sex in WT dams did not appear to affect 
maternal uterine angiogenesis. However, male fetal sex in TG dams was associated with 
fewer spiral arteries per placental unit (p<0.01). Maternal spiral arteries were also shorter 
and did not coil as often when the pup was a male in TG dams (p< 0.05).  
Angiogenic/Anti-Angiogenic Levels in Maternal Metrial Triangle at Mid-Gestation 
 Concentrations of VEGF, PLGF, and sFlt1 were impacted by maternal genotype 
and fetal sex in the metrial triangles sampled at mid-gestation (Figure 3.2). Gestational 
age GD12.5 was suboptimal to evaluate the angiogenic milieu provided peak 
angiogenesis occurs around GD8.5 (40), but specific microdissection of the metrial 
triangle away from the fetoplacental unit was not possible in our hands before GD12.5 
(confirmed by histologic analysis of microdissected tissues). Nonetheless, at GD12.5 the 
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metrial triangles in the placental beds of male pups from TG dams showed significantly 
less PLGF (p<0.05) and more sFlt1 (p<0.01) compared with males from WT dams. 
Females from TG dams showed no difference in VEGF or PLGF levels vs WT, but they 
too showed slightly more sFlt1 (p<0.05). Overall, the ratio of sFlt-1 (anti-angiogenic) 
over angiogenic factors like VEGF and PLGF was significantly greater in males from TG 
dams compared with all other groups (p<0.001).  
 
Figure 3.1. Uteroplacental 3D microCT perfusion to assess spiral artery structure. A) 
Representative microCT images of uterine spiral arteries at day 16.5 metrial triangles from WT and 
TG dams divided by fetal sex. B) Quantification of spiral artery number and average coiling score 
(mean ± SEM). Asterisks indicate significant differences between sex-matched placentas from WT 
and TG dams within each metric by student t-test (*: p<0.05, **: p<0.01, ***: p<0.001).  
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uNK Cell Activity and Angiogenesis in Metrial Triangle at Gestational Days 6.5 and 8.5 
 Activation of decidual uNK cells in early gestation were measured as a ratio of 
Ly49 (inactive) to DBA (active) as previously published by the Croy laboratory (23). 
Females from both WT and TG dams reduced their ratio of Ly49 to DBA positive cells, 
indicating uNK cell activation, from GD6.5 to GD8.5 (Figure 3.3). Compared to Dr. 
Figure 3.2. Angiogenic and anti-angiogenic factors concentrations in GD13 metrial triangle. All 
panels are mean ± SEM. A) VEGF and B) PLGF (angiogenic). C) sFLT (anti-angiogenic).  
D) Anti-angiogenic to angiogenic ratio with angiogenic factor VEGF and E) PLGF. Asterisks indicate 
a significant difference between sex-matched WT and TG mice (*: p<0.05, **: p<0.01, ***: p<0.001). 
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Croy’s previously published values in mice, data from WT mice in our study compared 
favorably (Figure 3.3A, B). Overall, pups from TG dams showed less uNK cell activation 
compared to WT, but this was largely a function of failure to activate uNK cells in 
metrial triangles related to male pups (Figure 3.3A—no change from GD6.5 to 8.5). 
Females from TG dams were relatively more activated compared with WT controls 
(Figure 3.3B), but not significantly different than published Croy expected values (23).  
 The potential impact of differences in metrial uNK cell activation and 
angiogenic/anti-angiogenic composition on spiral artery architecture was measured by 3D 
microCT at GD16.5 (late term). To investigate the potential impacts of fetal sex on early 
vasculogenesis and angiogenic pruning in the metrial triangle, we stained whole mounts 
at GD6.5 and GD8.5 for CD31 to highlight the vascular networks in the metrial triangle 
and measure vasculogenic “blebbing” as defined by Dr. Anne Croy’s group (41) and 
vascular branching/area. There was reproducibly less vascular blebbing in the metrial 
triangles of TG dams compared to WT controls independent of fetal sex (Figure 3.3C). 
Fetal sex differences arose when analyzing the branches/area, which is a measure of 
vascular pruning to create proper arterial networks (41). Pruning occurs after GD6.5 
yielding fewer total vascular branches per unit area (Figure 3.3D). Males from TG dams 
showed pruning results similar to those from WT dams, but females from TG dams did 
not prune their vascular networks as readily (Figure 3.3D). We suspect less pruning in 
females from TG dams could be a compensatory response to the relatively reduced 
vasculogenic blebbing driven by the TG phenotype. The consequence could be relatively 
normal spiral artery architecture in females from TG dams by GD16.5, which is clearly 
absent in males from TG dams whose corresponding metrial triangles continued pruning 
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Figure 3.3. Early gestation comparisons of TG vs. WT, GD6.5 vs. GD8.5. A & B) uNK cell activation 
expressed as ratios (Ly49/DBA+) divided by fetal sex (A) Males, B) Females). An increase in DBA+ cells 
indicates uNK activation. Ly49 positive cells are inactive uNK cells. Asterisks indicate significant 
differences between sex-matched WT and TG mice by two-way ANOVA (*: p<0.05, **: p<0.01, *8*: 
p<0.001). Significance of interest between groups (*: p<0.05; **: p<0.01; ***: p<0.001): WT 6.5 F and TG 
6.5 F: ***; WT 6.5 M and WT 6.5 F: **; WT 6.5 F and WT 8.5 F: ***; TG 8.5 M and TG 8.5 F: *. 
Trending of interest: TG 6.5 F and TG 8.5 F: 0.0969. C & D) Vascular changes divided by fetal sex. CD31 
was used as a vascular endothelial marker. Number of branches and vascular blebbing were all considered 
as markers of angiogenesis. Asterisks indicate significant differences between sex-matched WT and TG 
mice by two-way ANOVA (*: p<0.05, **: p<0.01, ***: p<0.001). C) Degree of blebbing. Increased 
blebbing metric indicates increased “blurriness,” an indicator of branching angiogenesis. D) Number of 
branches as compared by fetal sex. 
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Figure 3.4. Placental weight, 
efficiency, and capillary 
density. A) Placental weights. 
No statistical difference was 
observed between groups. B) 
Placental efficiency (ratio of 
fetal weight over placental 
weight). C) Statistical analysis 
of capillary density between 
groups (mean ± SEM). Asterisk 
indicates significant difference 
between labyrinth capillary 
formation in sex-matched WT 
and TG mice. *: p<0.05, **: 
p<0.01, ***: p<0.001. 
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vascular networks despite depressed vasculogenesis. We hypothesize that uNK cell 
activation leads to less pruning with females from TG dams showing the most uNK cell 
activation at GD8.5 (Figure 3.3B) and least amount of pruning (Figure 3.3D). In contrast, 
males from TG dams show the least amount of uNK activation and most pruning. 
Placental Histopathology, Nutrient Transport, and Transcriptomic Analysis  
 Males from TG dams were smaller than males from WT dams both at GD16.5 
(0.48 +/- 0.03g vs. 0.55 +/- 0.02g (p=0.05)) and at birth (1.29 +/- 0.02g vs. 1.46 +/- 0.04g 
(p=0.02)), but females only showed a difference at birth (GD16.5 0.48 +/- 0.04g vs. 0.52 
+/- 0.02g (NS), birth 1.23 +/- 0.01g vs. 1.37 +/- 0.02g (p<0.001)). Placental weights were 
similar between groups. Males from TG dams had a significantly lower fetal:placental 
weight ratio (placental efficiency) compared with their female siblings (p=0 05, Figure 
3.4). Placental histopathologic stereometric analysis revealed fewer capillaries per unit 
areas in the placental labyrinths of males from TG dams compared with their female 
siblings and WT controls (Figure 3.4). Surprisingly, lipid and amino acid transport tended 
to be increased not decreased by the placentas of TG dams compared with WT controls, 
which was more pronounced in females from TG dams (Figure 3.5). 
 We elected to take both a candidate gene and more global transcriptomic 
approach to investigating why placentas from TG dams may have less angiogenesis and 
greater nutrient transport at GD16.5. First, transcriptomic analysis of microdissected 
placental tissue samples revealed that placentas from males from TG dams expressed far 
more genes than males from WT controls. There were minimal differences between 
females from TG and WT mice (Figure 3.6). 132 genes were similarly different in both 
males and females from TG dams compared with WT controls; gene ontology analysis 
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via DAVID revealed the most striking differences between TG and WT placental 
expression were related to upregulation of lipid transport pathways, upregulation of 
oxidation-reduction processes, and downregulation of negative regulators of the innate 
immune response, which implies an increase in placental inflammation. qRT-PCR 
Figure 3.5. Placental nutrient transport at day 16.5 gestation. A) Lipid transport measured by labeled 
arachidonic acid (AA). B) Amino acid transport measured by labeled methylaminoisobutyrate (MeAIB, 
highly selective for Amino Acid transport system in the placentas of males (M) and females (F).  
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Figure 3.6. Fetal sex and maternal transgene effect on global expression analysis. Volcano plots of 
distribution differences, comparing expression between A) males (top), B) or females (bottom) from 
different maternal genotypes. C) Venn diagram quantifying up versus downregulation of genes. D) 
Comparison of key gene ontology group of males from transgenic vs. wild-type dams as classified by 
DAVID. Red indicates overexpression of gene groups in transgenic males and includes groups involved in 
lipid metabolism and oxidative stress. Green indicates downregulation of the negative regulation of innate 
immune response in transgenic males. E) Correlation of RNASeq gene expression versus qRT-PCR. 
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validation of candidate genes within these pathways [Supplemental Table 3.1] correlated 
well with fold-changes observed in RNASeq data (Figure 3.6E).   
 
Discussion 
Our data suggest that the combination of maternal genetic predisposition and male 
fetal sex abnormally impacts maternal uNK cell activation, uteroplacental angiogenesis, 
placental gene expression, and placental nutrient transport compared with controls. These 
observations advance the field by showing for the first time that the placentas from males 
may interact and communicate differently with maternal uterine tissue than the placentas 
from females, which appear more resistant to the maternal AGT genetic risk factor. 
Maternal Genetic Predisposition for Fetal Growth Restriction 
 Several factors have been linked to increased likelihood of FGR, including 
maternal diet and maternal genetic factors. Angiotensinogen promoter variants have been 
associated with FGR in humans (42–44) and are the pretext for the TG mouse model used 
in our study. The A-6 promoter variant associated with FGR in humans is a common 
allele present in approximately 14% of Caucasians and imparts a 20-fold increased risk of 
having pregnancy complications compared with the G-6 allele. Similar risk has been 
reported in studies of Japanese women (45, 46). Several other maternal genes have also 
been shown to increase risk. For example, the single nucleotide polymorphism G-308A 
of TNF-α is associated with FGR, preterm birth, and increased infant mortality (47–49). 
Placentas with this TNF-α mutation were also more sensitive to increased Angiotensin II 
and released more inflammatory cytokines (50). Additionally, the 14-bp insertion into the 
3’-untranslated region of HLA-G coupled with an increased G*0106 allele frequency has 
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been reported to be more common in pregnancies complicated by preeclampsia and 
miscarriage (51). 
 To better understand the underlying pathophysiology of FGR, several mouse 
models have been developed to mimic the human condition. We used the AGT 3-copy 
transgenic mouse originally made by Dr. Oliver Smithies (52) backcrossed into our WT 
controls. This construct expresses 20% more systemic AGT than WT and presents with 
gestational hypertension and FGR, similar to women with the A(-6) promoter variant (31, 
45, 53). TNF-α knockout mice have been studied by others, which seems to protect 
against placental pathology caused by infection (54). More relevant to the placental 
insufficiency model, the endothelial nitric oxide synthase (eNOS) knockout model also 
demonstrates reduced uterine spiral artery angiogenesis and reduced placental nutrient 
transport (55). eNOS knockouts also show elevated superoxide production, which can 
affect metabolic function similar to what we observed in our model (56, 57). 
Angiogenic/Anti-angiogenic Axis 
 Males from TG dams increase release of anti-angiogenic sFlt1 without a 
corresponding increase of pro-angiogenic VEGF or PLGF. The pro- and anti-angiogenic 
ratios appeal to be critical hallmarks of FGR in our model. Both males and females from 
TG dams showed increased anti-angiogenic sFlt1 production detected in maternal blood 
and in metrial triangle tissue samples. However, only males from TG dams were 
associated with reduced VEGF and PLGF levels in the metrial triangles. This may 
explain why males were associated with less spiral artery and placental angiogenesis.  
 VEGF binds cell-surface tyrosine kinase VEGFRs for vascular and endothelial 
growth (58). PLGF, a member of the VEGF family, is structurally similar to VEGF and 
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shares a receptor, VEGFR-1. VEGFR-1 activation stimulates angiogenesis, but the 
location of VEGFR-1 activation is also important (60). Endothelial-mediated activation 
may have entirely different effects on angiogenesis than VEGFR-2 or VEGFR-1 
activation in the surrounding uterine decidua or vascular media. sFlt1 is the soluble splice 
variant of receptor VEGFR-1 and acts as an anti-angiogenic decoy molecule, binding and 
sequestering pro-angiogenic PLGF and VEGF. Notably, increasing Angiotensin II 
enhances release of sFlt1 by placental trophoblasts, leading to excessive sequestering of 
critical growth factors (61–63). 
Impact of Maternal Genotype and Male Fetal Sex on Spiral Artery Architecture 
Male fetal sex in TG dams, but not WT dams affected uteroplacental 
angiogenesis. Importantly, we excluded TG (3-copy) progeny from TG dams in our 
analyses. We only included 2-copy (WT) progeny from TG dams to control for this 
potential covariate. The additional confounding element of fetal AGT genotype is a 
subject of future studies by our group. Nonetheless, the “WT” (2-copy) genetic male 
progeny from TG dams affected maternal uNK cell activation, maternal uterine 
angiogenesis, and the final structure of maternal spiral artery architecture.  
The maternal uterine spiral arteries did not branch and coil in the placental beds of 
males from TG dams as much as their female siblings or WT controls. Spiral artery 
remodeling begins early in pregnancy and is complete by mid-gestation in mice (64). We 
tested for differences during the period when uNK cells begin to be activated (65, 66) and 
observed less uNK cell activation in the metrial triangles of males from TG dams, but not 
in their female siblings compared with WT controls. Notably, there were no significant 
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differences in uNK cell activation in males versus females from WT dams, suggesting the 
combination of maternal genetic risk and male fetal sex led to the abnormal phenotype.  
Uterine NK cells are thought to play a key role in modulating early angiogenesis 
and pruning to create proper spiral arteries for normal uteroplacental blood flow and 
nutrient delivery to the fetus (67). When activated, they release VEGF and stimulate 
angiogenesis, which we measured by the degree of blebbing (41) in whole mounts of the 
metrial triangle. They are then inactivated by mid-gestation as the angiogenic network is 
pruned into functional spiral arteries. Uterine NK cell activation begins early in 
pregnancy (GD6.5) and they are inactivated by mid-gestation (66). Our data suggest that 
male fetal sex somehow inhibits normal maternal uNK cell activation leading to less 
angiogenesis. Their female siblings also showed less angiogenic blebbing compared with 
WT controls, but they seemed to compensate by reducing the degree of vascular pruning 
at GD8.5, which may explain why these females had relatively normal spiral artery 
architecture after mid-gestation (GD16.5 measured by 3D microCT). We and others 
suspect that activated uNK cells may not only play a role in stimulating angiogenesis, but 
they may also modulate pruning (24, 68, 69). Poor uNK activation related to male fetal 
sex in TG dams may be the reason why we observe less angiogenesis and more pruning 
in males from TG dams.  
How the placenta communicates with maternal uNK cells is not entirely clear. In 
humans this may be through direct interaction or via T-cells and dendritic cells. 
Trophoblast invasion occurs near the end of first trimester human gestation and may 
allow for direct recognition of HLA class I molecules by uNKs to influence spiral artery 
remodeling and function (70). CD56+ uNKs interact with T cells to release interferon 
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gamma to protect against infection (71), or with dendritic cells via HLA-G and TNF-α 
antigens (54). In early gestation, uNKs are thought to partner via antigen presentation to 
T cells (predominantly CD8+) (66). In mice, however, uterine spiral arteries remodel 
before trophoblast invasion, so a paracrine signaling mechanism is more likely than a 
direct contact model. We are currently exploring this new concept by assessing both 
trophoblast invasion depth in murine spiral arteries and paracrine signaling by 
extracellular vesicles (EVs) released by the placenta targeting maternal uNK cells, 
endothelial cells, or other cells potentially involved in spiral artery angiogenesis. EVs 
may regulate maternal angiogenesis and immune functions by carrying placental signals 
to target maternal tissues (72). We hypothesize that proteins and small RNAs 
(microRNAs) are delivered by EVs to maternal cells. To test this, we have recently begun 
experiments on a Cre-loxP mouse dam expressing ubiquitous tdTomato and a placenta-
specific Cre sire. Cre recombination in a LoxP host cell will induce GFP expression in 
the placenta, released placental EVs, and transformed maternal tissues (73). 
Fetal Sex Affects Placental Gene Expression 
The main differences between placentas from males compared with females were 
related to upregulation of genes involved in nutrient transport and downregulation if 
immune response genes. There is little known about fetal sex effects on placental gene 
expression (19, 74). Our RNASeq data revealed a few expected fetal sex differences 
related to the expression of genes on X and Y sex chromosomes. Males from TG dams 
had lower expression of X chromosome genes linked to brain development (BEX family 
(75)), but higher expression of genes part of the infection response and 
lymphoproliferative pat hways (Sh2d1 family (76)) compared to sex-matched controls. If 
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X-linked gene differences play an important role in placental mediation of uteroplacental 
angiogenesis, relationships between fetal X chromosome aneuploidy and an increased 
risk for fetal growth restriction would be expected. This would be confounded by the 
known impact of aneuploidy in general leading to small placentas and small babies with 
the exception of Turner’s Syndrome (X0) (77–79). 
There were differences in fetal sex hormone production revealed by our RNASeq 
data. For example, male placentas from TG dams upregulate the gene HSD3B1, which 
encodes for 3-beta-hydroxysteroid dehydrogenase isomerase, an enzyme in the steroid 
synthesis pathway, and increased HSD3B1 increases progesterone and androgen levels 
(80–82). Progesterone blocks estrogen receptor 1 (ESR1) expression, which was notably 
reduced in male placentas from TG dams. This may be significant because ESR1 encodes 
for estrogen receptor alpha (ERα); knocking out ERα is known to reduce angiogenesis in 
mouse models (83, 84). In humans, males from gestational diabetic pregnancies also have 
decreased ESR1 (85). ESR1 likely regulates angiogenesis via the VEGF pathway, which 
is downregulated with reduced estrogen reception activity (86–88). 
Consequences of Abnormal Maternal Spiral Artery Architecture 
 In Chapter 2 we showed that differences in spiral artery architecture lead to 
differences in uteroplacental blood flow and placental damage. We could not control for 
fetal sex in those blood flow studies performed in vivo because of the limitations of 
ultrasound imaging resolution in mice at day 16.5. This is because we cannot accurately 
discriminate the precise location of each uteroplacental unit within the right and left 
uterine horns by ultrasound imaging. In the current study, however, we could precisely 
measure nutrient transfer by each placenta and relate these metrics to fetal sex. We made 
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these measurements late in gestation (GD16.5) to correlate with documented 
uteroplacental vascular architecture, uteroplacental blood flow, and known fetoplacental 
growth restriction at this gestational age in our mouse model. Provided that the placentas 
from TG dams are relatively smaller and more damaged than WT controls, we were 
surprised to observe significantly more lipid and amino acid transfer by placentas in TG 
dams. Placental transcriptomic data was also obtained from placentas at GD16.5 and 
predicted increased lipid and amino acid nutrient delivery at GD16.5. 
 We suspect that increased nutrient delivery in the placentas of TG dams late in 
gestation may be a compensatory mechanism rather than an underlying cause of FGR in 
this model. We did not test placentas earlier in gestation, but it is well known that other 
FGR models also show increased uteroplacental nutrient delivery later in gestation (89–
91). Future studies will test whether placental RNA expression and nutrient delivery are 
different in those from TG dams and related to fetal sex when examined at GD12.5; this 
is the earliest gestational age for reliable placental micro-dissection in our experience. 
Study Limitations 
 These observations are intriguing and may lead to a better understanding of why 
human males seem to be more likely to be stillborn, growth restricted, and why they are 
more likely to have developmental programming of adult onset diseases (8). A potential 
limitation of our study, however, is the assumption that humans and mice may share 
pathogenic mechanisms. Since mouse placentas are different than human placentas, it 
may not be a good model and the underlying mechanisms may be entirely different (92). 
It is true that human placentation and murine placentation differ in a number of ways, 
from overall structure to the criticality of trophoblast invasion (26, 93). However, both 
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animals grow uterine spiral arteries and both may share similar placental:maternal uterine 
interactions regulating this essential process (22, 26). The advantage of using a mouse 
model is the power of transgenics to mimic human maternal genotypes and the power of 
comparing males and female siblings from the same litters. Most importantly, animal 
models are required to sample uteroplacental tissues throughout gestation—an advantage 
not possible for human studies until better “liquid biopsies” of the uteroplacental 
environment are available.  
 This work provides new insights into the combined effects of maternal genetic 
risk and fetal sex. Our observations suggest that male fetal sex in high risk pregnancies 
may compound maternal pathology, perhaps due to differences in uNK cell activation 












Supplemental Table 3.1. Primer sequences for AGT and SRY PCR. PCR for 
AGTdup was used to determine copy number and differentiate between 2-copy and 3-
copy AGT mice. SRY was used to determine male fetal sex. 
 
Primer Name Sequence 
AGT oIMR0750 5’-ACACTCAGAGACCATGAGTACACC-3’ 
AGT oIMR0751 5’-GAGTTCACTACCCACAAGTCTCC-3’ 
SRY Forward 5’-AGAGATCAGCAAGCAGCTGG-3’ 
SRY Reverse 5’-TCTTGCCTGTATGTGATGGC-3’ 
 
Supplemental Table 3.2. Genes identified from gene ontologies for verification. 
Gene Name Selected Related Gene Ontology Groups p<0.05 RefSeq 
Fabp1 GO:0008289 NM_017399.4 
Fabp4 GO:0050727 NM_024406.2 




Cox1 GO:0020037, GO:0009055, GO:0055114 NCBI Gene ID: 17708 






Klrb1b GO:0045824, GO:0031342, GO:0031341 NM_030599.4 









Renal DNA Methylation and the Developmental Programming of Stress-Induced 
Hypertension in Male Mice 
 
Abstract 
 Fetal growth restriction is associated with developmental programming of adult 
onset hypertension, which may be related to differences in kidney nephron development. 
Prior studies have shown that maternal protein restriction is associated with reduced fetal 
nephrogenesis in rodent models. We hypothesized that a transgenic (TG) mouse model of 
fetal growth restriction may similarly affect fetal kidney development leading to adult 
onset hypertension. We employed a previously described murine angiotensinogen (AGT) 
gene titration model known to develop stress-induced hypertension in male mice with 3 
copies of AGT compared with 2 copies of the gene. In this study, we investigated 
whether fetal growth restriction in 2-copy mice from 3-copy TG dams (designated pTG) 
leads to developmental programming differences in kidney development and blood 
pressure compared with age- and sex-matched wild-type (WT) mice from WT dams. 
Progeny were tested at birth, as 2 week old “neonates,” and as adults (12 weeks old). We 
measured weights, tested for renal oxidative stress using the Hydroxyprobe assay, tested 
for renal DNA methylation differences, quantitated the number of nephrons/kidney by 
stereology, and measured adult blood pressure by radio-telemetry +/- stress induction. 
Our results show that progeny from TG dams were born about 10% smaller, they showed 
signs of fetal renal oxidative stress, and there were renal DNA methylation differences in 
their male pups, but the number of nephrons was not different at 2 weeks of age 
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compared with WT controls. By 12 weeks of age, however, 2-copy male progeny from 
TG dams had relatively smaller adult kidneys with fewer total nephrons and they 
developed stress-induced hypertension like their 3-copy male siblings. We conclude that 
developmental programming of hypertension may involve differences in post-natal 
kidney DNA methylation and subsequent growth, rather than reduced nephrogenesis.  
 
Introduction 
 Fetal growth restriction is associated with developmental programming of adult 
onset hypertension and cardiovascular disease (1-8). Although hypertension is a 
multifactorial disease, many studies have shown developmental programming related to 
the in utero environment is also a major contributor to the variance in adult blood 
pressure in humans (6-10) and in animal models (11-14). Animal models employed to 
investigate the underlying mechanisms typically use differences in maternal diet 
(macronutrient profile alteration), uteroplacental insufficiency generated by placental 
embolization (15), or surgical ligation of major vessels feeding the placenta (13, 16). 
These studies have yielded important insights into the relationship between placental 
insufficiency caused by differences in maternal nutrition or differences in blood flow to 
the placenta. However, severely restricted low protein maternal diets, or significantly 
decreasing blood flow to the placenta, are manipulations with known limitations that may 
not be applicable to most human pregnancies, especially in developed nations.  
 In contrast, our group employs a mouse model designed to mimic a common 
human angiotensinogen (AGT) genetic variant associated with chronic hypertension and 
obstetric complications of placental insufficiency in women (17-19). The murine AGT 
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gene duplication (3-copy) transgenic (TG) mouse model was originally generated and 
characterized by Smithies et al (19) to mimic the 20% increase in circulating plasma 
AGT levels observed in humans with the common A(-6)G promoter variant (17, 18). 
Smithies demonstrated that these 3-copy mice develop elevated blood pressure compare 
with controls by employing tail-cuff plethysmography (19). This blood pressure result 
has been challenging to reproduce with more recent radio-telemetry technology, however, 
suggesting that a relative “stress-induced hypertension” may be a more accurate 
phenotype of the 3-copy TG model.  
 We hypothesize that wild-type (WT) progeny from TG dams crossed with WT 
males may similarly develop “stress-induced hypertension” like their 3-copy siblings. In 
addition, since the progeny of TG dams are born relatively smaller than controls, we 
suspect that they may have fewer nephrons similar to other rodent growth restriction 
models (11). This would be important because reduced nephron number is associated 
with chronic hypertension in adult humans (20). Reduced nephron number also seems to 
be a consequence of placental insufficiency in adult rats (11, 21) and sheep (22). Notably, 
in rats, the kidney’s nephron number is established by post-natal day 10 (23). Maternal 
protein restriction in rats seems to affect nephrogenesis, rather than post-natal kidney 
development (21), but this is not entirely clear. Increased fetal oxidative stress could also 
play a role in this process (24). Therefore, our objective was to test whether placental 
insufficiency and fetal growth restriction in TG dams leads to elevated fetal renal 





Transgenic Mouse Model of Placental Insufficiency: Transgenic mice with 3 copies 
(AGTdup) of the murine Agt gene on a C57Bl/6J background (strain number B6.129P2-
Tg(AGTdup)1Unc/J), as well as control C57Bl/6J mice (WT) with the normal 2 copies of 
Agt, were obtained from The Jackson Laboratory (Bar Harbor, ME) and back-crossed 
into C57Bl/6J for at least 10 generations before performing the described experiments. 
Our group has previously published pregnancy-related experiments using this model (25). 
The colony is maintained under an IACUC-approved protocol # B11130 with free access 
to food and water. They are housed under standard temperature-controlled 12:12hr 
light:dark conditions. TG dams were generated de novo for each breeding experiment by 
using 3-copy females from WT dams bred with TG males. We had previously discovered 
that using TG females from TG dams caused significant generational effects 
(miscarriage, infertility, very small litter sizes) as a confounding variable. Therefore, for 
the purposes of these experiments, all TG females used for breeding were progeny from 
WT dams. At least 4 litters per maternal genotype were used for all experiments. 2-copy 
(WT) progeny from TG and WT dams were used for all analyses with the exception of 3-
copy male siblings used as positive controls for blood pressure studies (19).  
Genotype and Sex: AGT genotype and fetal sex were determined by PCR using specific 
primer sets that yielded products of expected size and DNA sequence: 
Agt oIMR0750 (from The Jackson Laboratory genotyping protocol)  
5’-ACACTCAGAGACCATGAGTACACC-3’ and  
Agt oIMR0751 5’-GAGTTCACTACCCACAAGTCTCC-3’); or  
Sry Fwd 5’-AGAGATCAGCAAGCAGCTGG-3’ and  
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Sry Rev 5’-TCTTGCCTGTATGTGATGGC-3’. Briefly, fetal livers were digested in 
Proteinase K overnight, then genomic DNA was isolated using the QIAgen DNeasy kit 
with the spin-column protocol (QIAgen, Inc., Valencia, CA). PCR was performed on the 
genomic DNA, in separate reactions, to determine 1) Agt genotype and 2) sex by 
presence or absence of the SRY gene. Both PCR reactions used the following cycling 
parameters: initial melting at 94C for 2 min; followed by 40 cycles of 94C for 20 s, 65C 
for 30 s, 72C for 30 s; followed by a final 72C extension for 5 min. All samples have the 
endogenous AGT genetic PCR product (160 bp), which served as an internal positive 
control for the PCR reaction. WT genotypes had only the 160 bp band; whereas, AGT 3-
copy mice (TG) showed both a 160 bp band and a 189 bp band for the AGTdup 
transgene. In the SRY reaction, a 249 bp band indicated male fetal sex; females lacked 
the SRY band, but retained the AGT product.  
Blood Pressure Measured by Radio-Telemetry +/- Stress Induction: At 12 weeks of age, 
progeny from TG (5 litters) and WT (5 litters) dams (litters used for birthweight studies, 
blood pressure studies, renal stereology) underwent surgical placement of carotid 
telemetric blood pressure transducers (Data Sciences, Intl., St. Paul, MN). Briefly, 
surgery was performed under anesthesia using inhaled isoflurane (O2 flow rate of 
1.5L/min & 4% isoflurane for induction; O2 0.5L/min and 1.5% isoflurane during 
surgery). Radio transmitters were placed in a subdermal pouch at the ventral abdominal 
area and then the probe was tunneled under the skin into the neck. The blood pressure 
transducer (Chronic Use TA11PA-C10 Implant, DSI) was then placed into the left carotid 
artery and secured with a suture. Animals were allowed to recover 7 days. The mean 
arterial blood pressures (BP) were measured each day beginning at 10 am for 4 
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consecutive days using PhysioTel telemetry receivers (model RPC-1, DSI) placed under 
each cage. Mean arterial pressure was recorded for 2 hrs using DataQuest Advanced 
Research Technology Gold Acquisition software (Version 2.20, DSI) with data points 
recorded as 15-second averages. The final 30 min of this 2-hr recording was reported as 
the BP at “REST.” After this rest period, mice were spontaneously STRESSED by briefly 
shaking the cage followed by loud music torture (Led Zeppelin) for a 30-minute 
recording period. The average values from 4 days of data collection were reported for 
each mouse as the REST or STRESS mean arterial pressures. Heart rate, systolic, and 
diastolic pressure were not measured in this experiment. Male 3-copy siblings from the 
TG litters served as blood pressure positive controls.  
Nephron Counting by Stereometry: After the completion of blood pressure studies, these 
12 week old mice were euthanized and their kidneys were harvested for analysis. They 
were each weighed, measured, cut in 2-mm thick transverse slices, fixed, paraffin-
embedded. Randomly sampled slices were embedded in Technovit (Heracus Kulzer 
GMBH, Wehrheim, Germany), and 3 sections (15-μm thick) were cut from the middle of 
the embedded slices; sections were stained with periodic acid-Schiff stain and 
hematoxylin, the 1st and 3rd stained sections were used for nephron counting as described 
previously (11). A separate section was stained with hematoxylin and eosin and analyzed 
for evidence of glomerulosclerosis by a pathologist (TKM) blinded to the experimental 
condition of the animal. In addition, to determine whether differences in nephrogenesis 
occur during development or after the post-natal period, we included a cohort of 
“neonatal” progeny harvested two weeks after delivery (day 14) from 5 WT and 5 TG 
litters. This timeframe was chosen to ensure complete development (23) without allowing 
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for the initiation of nephron dropout with increasing age. The area of the renal cortex in 
neonates was outlined and measured using ImageJ to provide a nephron density metric.  
Fetal Renal Hypoxia Analysis: To study the potential role of oxidative stress in fetal 
kidneys leading to nephron loss, we employed the commercially available Hydroxyprobe 
kit (Hypoxyprobe, Inc., Burlington, MA) injecting dams (n=4-6 litters per maternal 
genotype: TG, WT) intraperitoneally at e18.5 with 60mg/kg. After two hours, dams were 
anesthetized with isoflurane and one maternal kidney was transiently ligated as a positive 
control tissue for histologic analysis. Placentas were removed and fixed in formalin for 
paraffin-embedding and Hydroxprobe analysis. Fetal kidneys and livers were removed as 
described below for similar analysis. Tissue sections were immunostained in batch and in 
duplicate for 1) tissue hypoxia using the Hypoxyprobe kit (Hypoxyprobe, Inc.); 2) cell 
proliferation using Ki-67; and 3) evidence of apoptosis using an ApopTag kit (Sigma-
Aldrich, St. Louis, MO). Ligated maternal kidney served as a positive control for 
Hydroxyprobe studies; human endometrium was the positive control for Ki-67 and 
apoptosis. Sections were scored by an anatomic pathologist (tkm) and student who were 
both blinded to maternal phenotype as negative (0), weakly positive (1), or strongly 
positive (2). Discrepancies between reviewers were adjudicated and consensus scores 
were reported as the mean per fetal sex per litter.  
Fetal Kidney DNA Methylation Analysis: Genomic DNA was isolated from whole fetal 
kidneys (e18.5), then cut with restriction enzyme MseI, and enriched for methylated 
DNA using an anti-5-methyl cytidine antibody for DNA methylation analysis using a 
NimbleGen DNA Methylation Array performed by Roche-Nimblegen (Roche Sequencing 
Solutions, Madison, WI). CpG-specific log2-ratios were obtained from Roche-Nimblegen 
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(RNG) as PAIR files and processed by RNG's Detect_DMR algorithm (with "high-
sensitivity" setting and 750bp window). For each CpG, the algorithm pools of all probes 
within 750bp in either direction were applied to a linear mixed effects model with 
random intercepts representing probe effects and a fixed effects model representing 
progeny of Tg vs. controls log-fold-change. Using the qvalue package in R, nominal 
CpG-specific p-values were subsequently converted to q-values do derive false discovery 
rates. As a global comparison of sex-specific effects, the sex-specific array-wide 
distributions of fixed regression coefficients representing CpG-specific effects of progeny 
of Tg vs. controls, i.e. log-fold-changes were compared using the Kolmogorov-Smirnov 
test. All nominal p-values were Bonferroni-adjusted. In addition, using a published 
approach, values were adjusted to compensate for potential differences in cell 
composition in kidneys (26). This is important because unlike methylation studies using 
cell lines, whole organ analysis is confounded by mixed tissue composition and 
compensation must be made for potential differences between the contributions of 
metabolically active proximal tubes compared with interstitial stromal cells. Statistical 
adjustments for expected numbers of cell types and relative composition (provided by 
relative nephron density stereology studies in this case—see below) were used to 
generate volcano plots and unsupervised heat maps to compare groups.  
Statistical Methods: Weights, nephron number, and BP means were compared using two-
way ANOVA with Bonferroni post hoc analysis, using Maternal Genotype and Sex as 
factors. If significant interactions were found (PINT<0.05), sexes were analyzed separately 
using unpaired t-test with or without Welch’s correction for different variances as 
appropriate. For nonparametric measures (Hypoxyprobe, Ki-67, ApopTag), Mann 
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Whitney U tests were used to test effects of Maternal Genotype and Sex separately. For 
all tests, P<0.05 was considered significant. Data are presented as means ± SEM. 
 
Results 
Sex Differences in Fetal Growth Restriction and Adult Catch-Up Growth 
 The progeny of TG dams were growth restricted at birth (male (1.29 ± 0.04g; 
P<0.03) and female (1.23 ± 0.01g; P<0.0001)) compared with age- and sex-matched WT 
controls (1.46 ± 0.05g and 1.37 ± 0.02g, respectively). Interestingly, both sexes showed a 
relative drop in weight compared with matched WT controls at 1 week of age (Figure 
4.1). Following weaning at 3 weeks of age, body weights remained reduced in the TG 
progeny (P<0.0001 for males, P=0.0006 for females). They then showed catch-up growth 
with females slightly exceeding WT females by 12 weeks; however, males did not catch-
up (pTG males 29.75 ± 0.63g versus pWT males 32.17 ± 0.48g; P<0.02).  
Fetal Growth Restriction Leads to Stress-Induced Hypertension 
 There was no difference in mean arterial pressure at rest between any of the adult 
mice, including 3-copy male “positive controls” and progeny from TG and WT dams 
(Figure 4.2). However, similar to the likely stressor of tail-cuff plethysmography 
employed by Smithies’ group in his original characterization of this TG model (19, 27), 
we observed a statistically significant increase in BP in stressed 3-copy male controls 
(Figure 4.2A). Their 2-copy male siblings showed a less robust stress response, but they 
too demonstrated an increase in BP (P<0.05) compared with WT males exposed to the 
same stressors and measured at the same time. Females from TG dams did not have 
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Figure 4.1: Birthweight and Catch-Up Growth of Progeny from TG and WT Dams. The sex-specific 
mean body weight for 10 litters was averaged and presented as means ± SEM from birth through 12 weeks 
for the progeny of TG dams (closed triangles) relative to the body weight of age-matched WT controls 




Neonatal Renal Morphometry and Nephron Number                                                          
 At 2 weeks of age, neonatal nephron density within the renal cortex was very 
similar in males and females from TG and WT dams (Figure 4.3A). However, by 12 
weeks, their adult relations clearly showed fewer glomeruli/kidney in male progeny from 
TG dams (Figure 4.3B). We suspect this may be related to differences in post-natal 
kidney growth into adulthood, because kidney weights were very similar between groups 
in 2 week old neonates (pTG males 42.3 ± 1.8 mg versus WT males 44.3 ± 1.2 mg) but 
significantly less in adult pTG males compared with age-matched male WT controls  
Figure 4.3C). Interestingly, females from TG dams seem to have slightly larger kidneys 
with slightly more nephrons/kidney than WT females, but this was not statistically 
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Figure 4.2: Adult Resting and Stressed-
Induced Blood Pressure in Progeny of TG 
and WT Dams. Blood pressure for (A) males 
and (B) females shown as means ± SEM for 
progeny of TG dams (pTG) and WT controls. 
3-copy TG male progeny of WT dams served 
as the positive control for stress-induced 
increases in blood pressure for comparison to 
previous studies (19). Data are from adult WT 
progeny (males, n=5; females, n=6); age-
matched TG progeny (males, n=6; females, 
n=5); cross-hatched bar is data from 3-copy 
male positive controls (n=6). *Maternal 
genotype effect, P<0.05. 
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significant. Renal function was not compared between groups, but histologic examination 
of kidney sections by a renal pathologist revealed no diagnostic pathology (e.g. negative 
for glomerular sclerosis, arteriopathy, interstitial inflammation).  
 
Fetal Renal Oxidative Stress in Growth Restricted Progeny from TG Dams 
 Hypoxyprobe is an in vivo assay used to label relatively hypoxic tissues with a 
marker than can then be detected ex vivo by immunohistochemistry. Partially ligated 
maternal kidneys served as a positive control for the Hydroxyprobe assay and they 
reproducibly showed positive immunostaining in the proximal tubule cells, which were 
negative in the contralateral maternal kidney (data not shown). In TG dams, this control 
was not actually necessary because the placentas in these litters were strongly positive for 
Hydroxyprobe immunostaining. In contrast, none of the placentas from WT litters were 
positive. Fetal kidneys from TG dams similarly showed reproducible staining in their 
proximal tubules (Figure 4.4A), independent of fetal sex, which was absent in WT 
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Figure 4.3: Glomerular Number in 
Neonatal and Adult Progeny of 
TG and WT Dams. A) Nephron 
density in neonatal cohort . B) Total 
estimated nephron number in adult 
cohort determined by stereology. 
Adult kidney weight in grams (g) 
(C) and length (cm) (D). Data are 
shown as means ± SEM for male 
(n=4) and female (n=4) progeny 
from TG dams (pTG) and WT 
controls (male, n=6; female, n=8). 
§P<0.05, §§P<0.005, §§§P<0.0001; 
Sex: *P<0.05; Maternal genotype: 
**P<0.005. 
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controls (Figure 4.4A, B). To determine whether oxidative stress led to different 
compensatory responses in male and female fetal kidneys we immunostained serial 
sections for Ki-67 (proliferation marker) and ApopTag (apoptosis marker). Provided our 
stereology results from adults, we hypothesized that males from TG dams would have 
less Ki-67 and/or more tubular apoptosis compared with their female siblings. This 
hypothesis was incorrect. There was not statistically significant difference in tubular 
proliferation index, or apoptosis, between groups (Figure 4.4C, D).  
 
 
Figure 4.4: Fetal Kidney Oxidative Stress, Cell Proliferation and Apoptosis in Progeny of TG and 
WT Dams. Immunohistochemical staining levels for Hypoxyprobe (A) in fetal kidneys of WT and TG 
dams reveals positive signs of oxidative stress in the proximal tubules of both males and females from TG 
dams (B). There is no difference in the Ki-67 proliferation index (C) or renal tubular apoptosis by 
ApopTag (D) between groups. Data are shown as means ± SEM for male and female progeny. Data from 
5 litters per group with (WT: male, n=13; female, n=9); (TG: male, n=4; female, n=7).                     
***Maternal genotype effect, P<0.0001. 
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Fetal Kidney DNA Hypermethylation in Males from TG Dams 
 Since we did not observe differences in fetal kidney oxidative stress or nephron 
density in the neonatal cohort, we elected to screen flash frozen archived fetal kidney 
samples for potential epigenetic effects. We tested for differences in fetal renal DNA 
methylation using Roche NimbleGen DNA Methylation Microarrays. Dr. E. Andres 
Houseman (Biostatistician at Oregon State University) performed the analysis employing 
his published strategy (26) to compensate for the confounding effects of using mixed 
tissue samples (e.g. whole kidney rather than isolated proximal tubule cell line). The 
problem with mixed tissue DNA methylation analysis is they vary by cell composition.  
Figure 4.5: Global Promoter Methylation in Fetal Kidney in Progeny of TG and WT Dams. 
Distribution of log2-fold-changes in promoter methylation in males (dotted line) and females (solid line) 
from TG dams compared with age- and sex-matched WT controls. Volcano plots show no significant 
difference in fetal renal DNA methylation between female groups, but marked hypermethylation in males 
from TG dams. Unsupervised cluster analysis using global DNA methylation data or rank ordered data 
show relatively good separation between groups with accentuation of the H19 locus.  
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 The analysis revealed that the distribution of global DNA methylation in fetal 
kidneys from WT controls compared with TG dams (reported as the log2-fold-change) 
varied between male and female mice (Figure 4.5A; Kolmogorov-Smirnov P<10-15). It 
also showed that males had a much higher proportion of extremely large values – loci for 
which progeny of TG dams were hypermethylated relative to controls – than females. 
Volcano plots (Figures 4.5B and C) reinforced the point that males had a large number of 
nominally significant, large positive, hypermethylated loci relative to WT males and their 
female siblings from TG dams.  
 Unsupervised clustering of fetal DNA methylation profiles revealed relatively 
good separation of profiles from WT and TG progeny (Figures 4.5D, E). Data suggest 
H19 loci may be more hypermethylated in the progeny from TG dams compared with 
WT controls. However, our investigation into the distribution of log2-fold-change values 
between CpGs mapped to insulin-like growth factor genes thought to be involved in 
Figure 4.6. Targeted qRT-PCR analysis 
of insulin-like growth factor 2 (Igf2) and 
H19 relative to beta-actin housekeeping 
gene. Expression levels in fetal kidney 
RNA samples from males (blue) and 
females (pink) from wild-type (WT) and 
transgenic (TG) dams. We observed no 
differences in Igf2 levels between groups, 
but consistent with H19 DNA methylation 
studies males from TG dams had relatively 
suppressed H19 expression. Whether this 
contributes to their relatively decreased 
kidney growth from the post-natal period 
to adulthood is uncertain and requires 
additional studies.  
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nephrogenesis (Igf1, Igf1r, Igf2, Igf2r) were not statistically different by fetal sex (there 
may be trend, q=0.08). Pilot studies using qRT-PCR semi-quantitative expression 
analysis for Igf2 and H19 levels in fetal kidneys did not show any differences in insulin-
like growth factor 2 between groups, but there was less H19 expression in the fetal 




 Our data suggest that fetal growth restriction in this “physiologic” gene titration 
model of placental insufficiency is sufficient to affect fetal kidney DNA methylation, 
nephron number in adults, and the developmental programming of adult onset stress-
induced hypertension. This type of “hypertension” is not chronic hypertension and was 
insufficient in our model to lead to diagnostic kidney pathology. However, this type of 
“white-coat” hypertension (named for patients’ stress-induced elevations in blood 
pressure measured at doctors’ offices) is a well-recognized clinical risk factor for chronic 
hypertension and kidney damage (27).  
 The murine Agtdup 3-copy mouse model we employed was originally developed 
by Nobel Laureate Dr. Oliver Smithies (19, 27) to mimic a common human AGT 
promoter variant A(-6)G (17, 18) that is associated with a 1.2-fold increase in circulating 
AGT levels. Since AGT is the rate limiting substrate in the renin-angiotensin reaction, 
this elevation is thought to increase angiotensin II levels and shift the Guytonian 
volume:pressure distribution to a more vasoconstrictive phenotype (19). Women with this 
common human AGT genetic variant are also at an increased risk for developing 
placental insufficiency and obstetric complications (19), including fetal growth 
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restriction. We have previously studied this 3-copy mouse during pregnancy and found 
that it has a number of features similar to women with placental insufficiency (25). We 
now show that these mice also have fetal growth restriction. Moreover, the growth 
restricted mice have very similar post-natal growth curves to growth restricted humans 
who later develop cardiovascular disease (1, 2), including the post-natal “dip” in weight 
observed at 1 week in our mouse model in at 1 year of age in human studies.  
 The key finding in this study is developmental programming of stress-induced 
hypertension in male, but not female adults from TG dams. The genotype and sex of the 
progeny were strictly controlled and compared with age- and sex-matched WT controls 
from the same genetic background (C57Bl/6J). 2-copy progeny from TG dams do not 
have elevated AGT expression (19, 27) and they do not have elevated blood pressure 
when at rest. However, these mice did show stress-induced increases in mean arterial 
pressure similar to their 3-copy male siblings (19). It is important to point out that 3-copy 
male “positive controls” did not have elevated blood pressures measured by telemetry at 
rest. We explain this finding by suggesting that radio-telemetry may ameliorate the stress 
likely arising with tail-cuff constriction.  
We only observed a stress-induced increase in blood pressure in our model. It did 
not persist and was ameliorated within 24 hours in all of our animals. Other 
developmental programming models of adult-onset hypertension have reported sustained 
hypertension rather than stress-dependent hypertension. A potential anatomic correlation 
with those models is relatively fewer nephrons in the malnourished or growth restricted 
progeny. It was Langley-Evans who first showed that rat offspring exposed to maternal 
protein restriction in various periods of gestation developed programmed hypertension 
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(29) and these adult rats had reduced nephron numbers (21). Woods et al. published very 
similar results in her rat model (11, 30, 31) and also demonstrated that uninephrectomy 
shortly after birth led to hypertension in adults (32). Their work supported the idea that 
reduced nephron development may cause hypertension.  
We also observed fewer numbers of nephrons in adult males in our model, but not 
in our neonatal cohort and we did not appreciate a difference in the proliferation index or 
apoptotic frequency in fetal kidneys from cases and controls. We did observe evidence of 
increased oxidative stress in the proximal tubules of fetal kidneys from TG dams, but 
there were no fetal sex differences to explain the adult sex differences seen in this model. 
Despite the fewer numbers of glomeruli in adult males from TG dams, and their 
predilection for stress-induced hypertension, we did not identify renal pathology in their 
kidneys. Nonetheless, this is consistent with the observation secondary glomerular 
sclerosis is thought to require at least a 50% reduction in nephron number to develop this 
pathology (33). It may therefore not be surprising that the relatively young male adults 
(12 weeks of age) in our study did not have histologic evidence of renal pathology and 
they did not develop chronic hypertension.  
Investigations into the impact of these programming effects on older male and 
female mice from this model needs to be explored, but for now we emphasize the 
significance of the neonatal cohort and fetal renal hypermethylation studies. The neonatal 
cohort data suggest this model may not affect nephrogenesis. Instead, we suspect it may 
affect the overall growth of the kidney in male offspring, or lead to increased nephron 
dropout with aging. We now hypothesize that differences in renal DNA methylation may 
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play a role in this process, but more work is needed, including more targeted candidate 
gene methylation and expression studies. 
Why do male mice in this model have more DNA methylation and how could that 
lead to fewer nephrons/kidney without evidence of reduced nephrogenesis or glomerular 
pathology? The male fetus may respond to placental insufficiency by shunting blood 
away from less-vital organs (kidney, liver, etc.) to spare the growth of more-vital organs 
like the brain and heart (1, 2). Relatively hypoxic tissues paradoxically produce more 
reactive oxygen species via mitochondrial respiratory complex function (34). In turn, 
they are more prone to additional oxidative stress and epigenetic changes. Maternal 
hypoxia has been shown to increase reactive oxygen species production in the placenta 
(35) like we also observed in our model and we did observe evidence of oxidative stress 
in fetal kidneys. Perhaps males respond differently than females to this developmental 
stress? Loss of nephrons in adults does occur without diagnostic evidence of glomerular 
damage. For example, a recent study by Denic et al., using a combination of renal 
biopsies and serial imaging studies, showed that a substantial loss of nephrons through 
adult life in humans does occur without diagnostic glomerular sclerosis, or other clinical 
signs usually associated with nephron dropout (36). Therefore, our current working 
hypothesis is males from TG dams respond to oxidative stress with differences in renal 
DNA methylation that may predispose them to nephron dropout as they mature from 
neonates to adults. This hypothesis needs to be further explored in future studies.  
Alternative explanations should also be considered. For example, Bagby et al. 
showed there is microvascular hypersensitivity to norepinephrine in nutritionally-
programmed microswine offspring with stress-dependent hypertension (37). Indeed, 
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several laboratories have shown vascular hyperactivity to phenylephrine and other 
pressor effects in various programming models, including reduced uteroplacental 
perfusion (38) and in the progeny of eNOS knockout mice that do not properly grow and 
dilate uterine spiral arteries during pregnancy (39). We did not test for differences in 
sympathetic activity in our model, but this should be done.  
Finally, the clinical significance of white-coat hypertension should not be 
underestimated. It has been shown that repeated bouts of stress-dependent hypertension 
can progress to sustained hypertension (34)—like what commonly occurs in patients with 
sleep apnea (a growing clinical problem associated with the current obesity epidemic). 
Therefore, this mouse model may provide important insights into the pathologic 
mechanisms involved in developmental programming and the early signs of clinically 
















Concluding Remarks and Future Directions 
 
In this dissertation, we presented data supporting an overarching hypothesis that 
placental insufficiency leading to fetal growth restriction is a multifactorial process, 
which involves both maternal genetic risk factors and fetal sex. Chapter 1 defines the 
known pathophysiology of fetal growth restriction and divides this primary hypothesis 
into the three parts which became the focus of each data chapter of this dissertation: the 
maternal phenotype in FGR, the fetal phenotypes in FGR, and long-term health impacts 
of FGR on offspring.  
In Chapter 2, we tested whether a maternal genotype mimicking a common human 
angiotensinogen variant associated with fetal growth restriction affects uterine 
angiogenesis and pregnancy outcome. We demonstrated that this genotype leads to 
increased tissue-specific angiotensin II production and is associated with aberrant 
increases in the anti-angiogenic factor sFlt1, which sequesters available VEGF and may 
be responsible for reduced uterine spiral artery number and coiling in this model 
compared with wild-type controls. The consequence of abnormal uterine vascular 
remodeling was placental damage and fetal growth restriction. Notably, the phenotype 
could be rescued by transfecting uterine blood vessels with VEGF, which suggests the 
angiotensin/sFlt1/VEGF pathway plays a key role in pregnancy-induced uterine 
angiogenesis, supporting our hypothesis (Figure 5.1). 
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Because males are more likely to have 
significant pregnancy complications compared with 
their female siblings, in Chapter 3 we hypothesized 
that male fetal sex may somehow affect 
uteroplacental angiogenesis and nutrient transfer. 
By employing micro-dissection techniques we 
could compare fetal sex with placental architecture and maternal placental bed tissue 
(metrial triangle) expression levels. We observed that males in our mouse model were 
associated with an increased antiangiogenic sFlt1 level both in their placentas and in 
metrial triangle tissue samples. They also had less pro-angiogenic VEGF and PLGF 
expression. Their female siblings in this model also increased sFlt1 levels, but did not 
appreciably change their levels of VEGF or PLGF. This imbalanced ratio seen in males 
may be one reason maternal uterine spiral artery angiogenesis and placental capillary 
labyrinth angiogenesis are relatively suppressed. This is an entirely novel finding and 
required further investigation into potential mechanisms that could be involved in this 
process. 
In Chapter 4, we address the DOHAD consequences of FGR, particularly in terms 
of cardiovascular control as measured by blood pressure and renal development. We 
found adult males from our transgenic mouse model had elevated blood pressure in 
response to environmental stress and fewer nephrons in their kidneys compared to 
controls. Despite renal hypermethylation and elevated oxidative stress evident in the 
proximal renal tubules of GD18.5 FGR male mice, no reduction in nephrons were 
observed until adulthood. Females from TG dams showed increased fetal renal oxidative 
Figure 5.1. Working hypothesis. 
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stress compared to sex-matched controls. Although nephron density was not different at 2 
weeks postpartum, as adults these FGR females had an increased nephron density. Blood 
pressures from adult females from TG dams were the same as WT controls.  
uNKs and Angiogenic Impact 
We have postulated several mechanisms affecting the imbalance of 
antiangiogenic:pro-angiogenic factors seen in FGR midgestation. One such mechanism 
could be differences in maternal uterine NK cell activation, which is known to play a key 
role in the metrial triangle (and human decidua) to modulate local VEGF levels and 
mediate pregnancy-induced spiral artery angiogenesis. Males from TG dams had less 
activation of uNK cells during the critical GD6.5 to 8.5 uteroplacental vascular 
developmental window. During this same time period of development, maternal 
vasculogenesis (measured by scoring whole mount sections for vascular “blebbing”) was 
depressed in males in this model and by GD8.5 they had fewer vascular branches, which 
suggest either reduced angiogenesis or an over-active vasculogenesis “pruning” process. 
This important observation fits with what is known about uNK cell function during 
pregnancy. That is to say, uNK cells are the principal agents of spiral artery angiogenesis 
because they activate pruning in relatively low VEGF conditions, resulting in decreased 
vessel number (1, 2). 
 In our data, this “pruning” process turns out to be an important potential 
mechanism to explain our findings. It is a necessary physiologic adaptation to increase 
vasculogenesis in response to hypoxia and to organize these networks into functional 
arteries and capillary beds (3–5). In fact, others have also reported relatively deficient 
spiral artery growth in mice lacking uNK cells in the presence of low vascular growth 
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factor levels (6). A reduction in maternal uterine angiogenesis affects uteroplacental 
blood flow and maternal-fetal nutrient exchange (7). The sex difference may not only be 
limitations in males, but perhaps better compensation in females in our mouse model. 
Females from TG dams showed reduced “blebbing” compared with WT controls, but 
they seemed to compensate by differences in uNK cell activation and differences in 
pruning by GD8.5. They did not prune angiogenic networks as much as males did, which 
may be why females from TG dams did not have fewer or less coiled spiral arteries than 
WT controls. This may be related to the lower sFlt1/VEGF or PLGF ratio observed in 
female placentas. They did not show a reduction in VEGF in the metrial triangle the way 
males did, so it is possible that the lack of low VEGF signaling together with differences 
in uNK activation helped to “rescue” females from TG dams.  
Hormonal Regulation of Uteroplacental Vascular Growth 
Another indication of possible compensatory responses by female placentas to the 
TG maternal uterine environment is the expression differences we observed in female 
placentas compared with their male siblings. Our RNASeq data point to potential 
differences in sex hormone production by these placentas. As discussed at the end of 
Chapter 3, male placentas from TG dams upregulate the gene HSD3B1, which encodes 
for 3-beta-hydroxysteroid dehydrogenase isomerase that drives production of placental 
progesterone and androgens (8–10). Progesterone blocks estrogen receptor 1 (ESR1) 
expression and we reproducibly observed reduced ESR1 levels in male placentas from 
TG dams (Figure 5.2). This may be significant because ER is known regulator of 
angiogenesis. The mechanism is likely complex, however, because decreased VEGF is 
also associated with reduced estrogen reception activity (11–13). Interestingly, males 
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from human gestational diabetic pregnancies, another form of placental insufficiency, 
also have decreased ESR1 (14). Increased HSD3B1 is also linked to increased 
testosterone (15). Increasing maternal testosterone was recently found in another study to 
reduce uterine blood flow and spiral artery remodeling; moreover, the magnitude of these 
changes were greater in males than females (16). 
Placental Extracellular Vesicle Release and Maternal Response 
In mice, uterine spiral arteries remodel before trophoblast invasion, so a direct 
contact model is unlikely, but placental paracrine signaling may be the mechanism. We 
are currently investigating this new concept by validating both murine invasion, where 
we expect to see no difference, and paracrine signaling by extracellular vesicles (EVs). 
EVs have been shown to target specific cells and affect their function via delivery of 
proteins and RNA (17–19). Fetal placentas may be using EVs to regulate maternal 
angiogenesis and immune functions similar to how neoplasms (i.e. cancers, tumors) may 
regulate their microenvironments (20, 21). EVs are thought to regulate maternal 
Figure 5.2. Influence of maternal angiotensinogen and male fetal 
sex on expression of HSD3B1 and ESR1, as potential drivers of 
reduced uteroplacental angiogenesis in early gestation. 
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angiogenesis and immune functions by carrying placental signaling cargo to target tissues 
(20). To test the action of EVs, our laboratory has recently begun experiments employing 
a Cre-loxP mouse transgenic model with tdTomato expression in the dam and a placenta-
specific Cre sire. Crossing the two causes Cre recombination at loxP flanking sites and 
allows Cre-mediated removal of DsRed-stop, changing expression from DsRed+ to 
eGFP+ in placental cells (while allowing DsRed+ cells to serve as a positive control), 
including EVs released by the placenta and any cells transformed by EV products (22, 
23). Our preliminary data indicate that the placenta releases EVs continuously over the 
course of pregnancy, and by late gestation, the maternal kidney proximal tubules express 
eGFP instead of DsRed (Figure 5.3). This may be indicative of transformation by 
placental EVs, which we plan to assess by testing for the presence of Cre mRNA to 
verify expression and transformation of the kidney. The purpose of the placenta for 
Figure 5.3. Maternal tomato loxP mouse crossed with placental driven Cre male creates GFP 
positive fetal placentas that over-express Cre. Placental EVs released into the maternal blood 
appear to interact with the maternal kidney leading to GFP upregulation in proximal tubules.  
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releasing EVs and influencing other cells is currently unknown, but could play a role in 
controlling vascular tone.  
DOHAD Implications of Placental Insufficiency 
 Developmental programming of stress-induced hypertension affected male, but 
not female adults from TG dams, by reducing the number of adult nephrons and causing 
increased blood pressure. Our lab previously found that 2-copy mice expressed increased 
angiotensinogen in the proximal renal tubules compared to 3-copy mice, which led to 
situational hypervolemia (24). As we only considered 2-copy male mice from 3-copy 
dams for analysis, it is possible that reduced nephron counts as a result of FGR combined 
with hypervolemia could lead to the observed increased hypertension and hyperfiltration 
(25). Males have higher morbidity and mortality associated with chronic kidney disease 
and renal issues, and early evidence indicates testosterone may be a detrimental factor 
dividing male and female renal pathology (26). Experiencing later acute renal injury such 
as exposure to heavy metals, Hepatitis C or HIV infection, or malignancy would further 
exacerbate this condition (27).  
 This work has explored the links between FGR and maternal factors, fetal sex, 
and developmental programming of disease. Many studies still do not separate data by 
fetal sex despite being long recognized as a data confounder. The research presented in 
this dissertation strongly supports consideration for the impact of fetal factors on 
gestational maternal response, postnatal outcomes, and adult disease. Potential 
mechanisms addressed in this chapter provide ample future directions for this promising 
research in an effort to better address improving the state of maternal and fetal health. 
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